Machine learning enables the use of spectroscopic MRI to guide radiation therapy in patients with glioblastoma by Gurbani, Saumya Suresh
 
 
MACHINE LEARNING ENABLES THE USE OF SPECTROSCOPIC 





















Saumya Suresh Gurbani 
 
 





In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy in the 







Emory University School of Medicine 




COPYRIGHT © 2019 BY SAUMYA GURBANI 
 ii
MACHINE LEARNING ENABLES THE USE OF SPECTROSCOPIC 


























Dr. Hyunsuk Shim, Advisor 
Department of Radiation Oncology 
Emory University School of Medicine 
Department of Biomedical Engineering 
Georgia Institute of Technology 
 Dr. Lee Cooper, Advisor 
Department of Biomedical Informatics 
Emory University School of Medicine 
Department of Biomedical Engineering 




Dr. Melissa Kemp 
Department of Biomedical Engineering 
Georgia Institute of Technology 
 Dr. Peng Qiu 
Department of Biomedical Engineering 
Georgia Institute of Technology 
 
   
Dr. Hui-Kuo Shu 
Department of Radiation Oncology 
Emory University School of Medicine 
 
 Dr. David Yu 
Department of Radiation Oncology 
Emory University School of Medicine 
 
   




The work in this dissertation could not have been completed without the support of 
many members of an interdisciplinary and interinstitutional team. First and foremost, 
thanks go to my co-advisors, Drs. Hyunsuk Shim and Lee Cooper, who have guided me 
throughout my doctoral research and whose continued support I look forward to throughout 
my career. Next, the many members of our research team at Emory: Dr. J. Scott Cordova, 
Dr. Hui-Kuo Shu, Dr. Brent Weinberg, Dr. Eduard Schreibmann, Dr. Jeffrey Olson, Mr. 
Michael Larche, Mrs. Sarah Basadre, Mr. Robert Smith, Ms. Samira Yeboah, Mr. Karthik 
Ramesh, Dr. Zhongxing Liang, Dr. Eric Salgado, Dr. Younghoon Yoom, Dr. Youn Oum, 
Dr. Lei Zhou, Mr. Pooya Mobadersany, Ms. Safoora Yousefi, and Dr. Mohamed Amgad; 
and to our collaborators: Dr. Andrew Maudsley, Mr. Sulaiman Sheriff, Dr. Eric Mellon, 
Dr. Peter Barker, Dr. Lawrence Kleinberg, and Dr. Sineyob Ahn. Finally, thanks go to the 
members of my dissertation committee heretofore not mentioned for their guidance in 
preparing this work: Dr. Melissa Kemp, Dr. Peng Qiu, and Dr. David Yu. 
I’d also like to thank the Emory University Medical Scientist Training Program and 
its leadership: Dr. Robert Gross, Dr. Mary Horton, Dr. Cathy Quinones-Maeso, and Ms. 
Erica Weaver. 
I’d like to acknowledge my family and friends who have supported me throughout 
the past four years. To my parents, who have inspired me throughout my life; to my brother 
and sisters; to my fiancée and best friend, Sarah Dupont; and to my  friends who have been 
there through thick and thin. 
 iv
Finally, and importantly, I’d like to thank the patients who have graciously agreed 
to be a part of this research; they are the reason we pursue this research, so that we may 













TABLE OF CONTENTS 
ACKNOWLEDGEMENTS iii 
LIST OF TABLES vii 
LIST OF FIGURES viii 
LIST OF SYMBOLS AND ABBREVIATIONS ix 
SUMMARY x 
CHAPTER 1. Introduction 1 
1.1 Therapy for Glioblastoma 1 
1.1.1 Epidemiology 1 
1.1.2 The role of imaging in glioblastoma 3 
1.2 Magnetic resonance spectroscopy 5 
1.2.1 Whole-brain spectroscopic MRI identifies occult tumor 7 
1.3 Current Challenges for sMRI 10 
1.3.1 Spectral Fitting 10 
1.3.2 Inter-subject Comparison 13 
1.3.3 Quality Analysis 15 
1.4 Machine Learning 16 
1.5 Machine Learning for Magnetic Resonance Spectroscopy 20 
1.5.1 Quality Analysis 20 
1.5.2 Spectral Fitting 21 
1.6 Specific Aims 22 
CHAPTER 2. A CNN for Spectral Artifact Filtering 25 
2.1 Author's Contribution and Acknowledgement of Reproduction 25 
2.2 Abstract 26 
2.2.1 Purpose 26 
2.2.2 Methods 26 
2.2.3 Results 26 
2.2.4 Conclusion 26 
2.3 Introduction 28 
2.4 Methods 31 
2.4.1 Image Acquisition and Processing 31 
2.4.2 Data Labelling and Consensus 32 
2.4.3 Network Architecture 36 
2.4.4 Bayesian Optimization 38 
2.4.5 Gradient-weighted Class Activation Mapping 39 
2.5 Results 39 
2.5.1 Training and Validation 39 
2.5.2 Gradient-weighted Class Activation Mapping 44 
2.5.3 Whole-brain Pipeline 46 
 vi
2.6 Discussion 49 
2.7 Conclusion 54 
CHAPTER 3. The Brain Imaging Collaboration Suite 56 
3.1 Author's Contribution and Acknowledgement of Reproduction 56 
3.2 Abstract 57 
3.3 Introduction 58 
3.4 Materials and Methods 60 
3.4.1 Software Architecture 60 
3.4.2 Visualization and Contouring 63 
3.4.3 Normalization of Metabolite Values 63 
3.4.4 Automated Segmentation of Residual Contrast Enhancement 66 
3.4.5 Patient Imaging 68 
3.4.6 Radiation Therapy Planning 69 
3.5 Results 73 
3.6 Discussion 75 
3.7 Acknowledgements 76 
CHAPTER 4. Deep Learning For Spectral Fitting 77 
4.1 Author's Contribution and Acknowledgement of Reproduction 77 
4.2 Abstract 78 
4.2.1 Purpose 78 
4.2.2 Methods 78 
4.2.3 Results 78 
4.2.4 Conclusion 78 
4.3 Introduction 80 
4.4 Methods 84 
4.4.1 Image Acquisition and Processing 84 
4.4.2 Convolutional Encoder – Model Decoder 85 
4.4.3 Whole-brain Mapping 92 
4.5 Results 93 
4.6 Discussion 105 
4.7 Conclusion 110 
CHAPTER 5. Conclusion 111 
References                116 
 
 vii
LIST OF TABLES 
Table 1.1: Summary of literature on machine learning for spectral fitting ...................... 22 
Table 2.1: Consensus rating of spectral quality by a panel of MRS experts. ................... 35 
Table 2.2: CNN classifications of the discordant data set. ............................................... 41 
Table 2.3: Feature vector generated by MIDAS used for training a random forest. ........ 41 
Table 3.1: Summary of target volume definitions and dose prescriptions. ...................... 72 
Table 4.1: Subject-wise comparison of CEMD and MIDAS. ........................................ 102 




LIST OF FIGURES 
Figure 1.1: Sample single-voxel MRS of the brain from a vendor-provided sequence. .... 6 
Figure 1.2: Spectroscopic MRI (sMRI) of a patient with glioblastoma. ............................ 9 
Figure 1.3: The Cho/NAA ratio can identify occult regions of GBM infiltration. ........... 10 
Figure 2.1: Sample gallery of sMRI spectra. .................................................................... 29 
Figure 2.2: A web interface for MRS expert ratings. ....................................................... 33 
Figure 2.3: Schema of the spectral quality CNN and its training process. ....................... 37 
Figure 2.4: Spectra quality CNN performance versus MRS experts. ............................... 42 
Figure 2.5: Ranking of random forest feature vector by relevance. ................................. 43 
Figure 2.6: GradCAM analysis of representative poor quality spectra. ........................... 45 
Figure 2.7: GradCAM analysis of an idealized good quality spectrum. ........................... 46 
Figure 2.8: Application of spectral quality CNN to whole-brain metabolite heatmaps. .. 48 
Figure 2.9: Effect of class imbalance on CNN performance. ........................................... 54 
Figure 3.1: Schema of BrICS architecture. ....................................................................... 62 
Figure 3.2: The main user interface for BrICS. ................................................................ 64 
Figure 3.3: The BrICS contouring module. ...................................................................... 65 
Figure 3.4: Schema of the Gaussian mixture model for NAWM segmentation. .............. 67 
Figure 3.5: Algorithm for automated residual contrast enhancement segmentation. ....... 68 
Figure 3.6: Radiation therapy planning workflow for sMRI-based dose escalation. ....... 71 
Figure 3.7: Example treatment plan for study patient....................................................... 74 
Figure 4.1: Schema of a general autoencoder. .................................................................. 83 
Figure 4.2: Schematic of the convolutional encoder – model decoder (CEMD) 
architecture. ....................................................................................................................... 87 
Figure 4.3: Detailed schematic of the CEMD architecture. .............................................. 90 
Figure 4.4: Example spectral fittings generated by CEMD .............................................. 95 
Figure 4.5: Sample spectra (real components) from scans of subjects with glioblastoma.
........................................................................................................................................... 96  
Figure 4.6: Comparison of metabolite values computed by MIDAS and CEMD. ........... 98 
Figure 4.7: Comparison of CEMD and MIDAS spectral fittings on challenging spectra. 99 
Figure 4.8: Example whole-brain metabolite maps generated by CEMD for a patient with 
glioblastoma. ................................................................................................................... 100 
Figure 4.9: Comparison of the Cho/NAA volumes generated by MIDAS and CEMD in a 
subject with glioblastoma. .............................................................................................. 103 




LIST OF SYMBOLS AND ABBREVIATIONS 
AUC area under the curve 
CEMD convolutional encoder – model decoder 
Cho choline 
CNN convolutional neural network 
Cr creatine 
DSC Dice similarity coefficient 
EPSI echo planar spectroscopic imaging 
FLAIR fluid-attenuation inversion recovery 
GPU graphical processing unit 
MIDAS Metabolite Imaging and Data Analysis System 
MRS magnetic resonance spectroscopy 
MRSI magnetic resonance spectroscopic imaging 
NAA N-acetylaspartate 
ppm parts per million 
RMSE root-mean-squared error 
ROC receiver-operator characteristic 
RT radiation therapy 
sMRI spectroscopic magnetic resonance imaging 
T Tesla 
WHO World Health Organization 
𝜙  zero-order phase shift 
𝜙  first-order phase shift 
 x
SUMMARY 
Glioblastoma is the most common adult primary brain tumor and is highly 
aggressive due to its diffusely infiltrative nature. Radiation therapy has been shown to be 
the best single treatment for improving prognosis but requires accurate pre-therapy imaging 
for proper radiation planning. Spectroscopic magnetic resonance imaging (sMRI) is an 
advanced imaging modality that measures specific in vivo metabolite levels within the 
brain and has shown to be highly sensitive and specific in the detection of proliferative 
pathology. Clinical application of sMRI has been extremely limited due to computational 
challenges in sMRI data analysis. In this work, we utilize novel machine learning 
architectures to develop a software framework to close the gap for clinical utilization of 
sMRI in radiation therapy planning. First, we develop convolutional neural network to 
identify and remove spectral artifacts that lead to erroneous measurement. Next, we 
develop an algorithm for internally normalizing sMRI volumes, enabling voxel-to-voxel 
comparison across subjects and allowing threshold-based techniques to be used for target 
delineation. Third, we create a novel unsupervised learning framework to perform 
accelerated spectral quantitation, reducing the computational time and power needed to 
utilize sMRI. Finally, we develop a web-based software framework that bridges the gap 
between sMRI and its clinical use and demonstrate the feasibility of using this software in 
a multi-site clinical study to guide a radiation boost to regions of metabolic abnormality in 





As advances in precision medicine continue, medical imaging will serve as a central 
component in the diagnosis, monitoring, and prognostication of diseases. Medical imaging 
enables physicians to gain insight into a disease state and provide supplemental information 
to the clinical workup. To quote a 2003 opinion paper in the American Journal of 
Roentgenology: “To strike a target, it is necessary to see it. […] In what context does the 
contemporary physician most frequently encounter the internal anatomy of the human 
body? […] For most physicians, […] the answer is radiology.” (1) The necessity of medical 
imaging is highly evident in the clinical workflow for patients with brain cancers, where 
imaging comes into play from the time of diagnosis throughout treatment and follow-up. 
In this work, we focus specifically on the use of an advanced imaging technique, 
spectroscopic magnetic resonance imaging, for patients with glioblastoma. 
This chapter begins with literature reviews of the standard-of-care therapy for 
glioblastoma, of spectroscopic magnetic resonance imaging, and of the use of machine 
learning in the medical imaging field. It concludes with a presentation of the specific aims 
of this dissertation. 
 
1.1 Therapy for Glioblastoma 
1.1.1 Epidemiology 
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Glioblastoma, previous referred to as glioblastoma multiforme or GBM, is a highly 
aggressive primary brain tumor of glial cells. Glial cells are the neuron-supporting cells of 
the brain, playing a variety of roles in maintenance of neuronal health, including: 
myelination of neuronal axons, formation of the blood-brain barrier, regulation of the 
neuronal environment, and maintenance of necessary levels of blood-borne nutrients and 
oxygen to neurons (2). There are three main classes of glia in the central nervous system: 
microglia, astrocytes, and oligodendrocytes. Molecular mutations and pathway 
dysregulations in each of these types can lead to tumors, collectively known as gliomas. 
Historically, gliomas were classified by cell-type and their appearance on histological 
pathology. Recent work by consortia such as The Cancer Genome Atlas led in 2016 to new 
classifications by the World Health Organization (WHO) for gliomas based on molecular 
subtype and genetic mutations (3). This codification enables a better understanding of the 
underlying causes of these tumors and the progression of disease from low-grade gliomas 
to high-grade gliomas. Glioblastoma is the WHO Grade IV glioma, formed from 
unchecked proliferation of astrocytes. Glioblastomas are the most common amongst the 
malignant primary adult brain tumors, accounting for 15% of all neuroepithelial 
malignancies, with an incidence in the  United States of 3.2 per 100,000 persons (4). 
The standard of care for patients with glioblastoma is an aggressive regimen 
consisting of surgery, radiation therapy (RT), and chemotherapy (5). First, patients will 
undergo maximal safe surgical resection (debulking) of the tumor. Next, high dose 
radiation will be delivered to the surgical cavity and any residual tumor. For both surgery 
and RT, medical imaging is necessary to define targets for treatment. Concurrent and 
adjuvant chemotherapy with temozolomide, a DNA alkylating agent and the first-line 
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chemotherapy for glioblastoma, is continued throughout the patient’s disease course. 
However, despite these aggressive treatments, median survival remains poor at just 15 
months post-diagnosis (5). There are several hypotheses as to why this regimen still leads 
to poor outcomes, one of which is based on the presence of tumor that is undetected by 
standard medical imaging protocols and is discussed in the next section. 
 
1.1.2 The role of imaging in glioblastoma 
Magnetic resonance imaging (MRI) is the imaging modality used for diagnosing and 
planning treatment for patients with glioblastoma. MRI relies on the quantum spin of 
charged particles (e.g. protons) and how this spin can be manipulated in a magnetic field 
to yield a detectable imaging signal that can differentiate tissues of interest. Two different 
MRI techniques are commonly used which provide complementary sensitivity and 
specificity of tumor detection.  
High dose RT is targeted using a technique known as contrast-enhanced T1-weighted 
magnetic resonance imaging (CE-T1w MRI). In this imaging modality, an external contrast 
agent, typically gadolinium, in injected intravenously into the patient. In the healthy brain, 
the gadolinium from the systemic blood supply will not be able to enter the brain because 
of the intact blood-brain barrier. The blood-brain barrier is composed of astrocyte foot 
processes and the endothelial cells of cerebral blood vessels, which together form a barrier 
that limits the free diffusion of large or highly charged particles across the endothelial cell 
membrane (6). In glioblastoma, however, the blood-brain barrier breaks down in the most 
proliferative sections of tumor, allowing compounds such as gadolinium to leak into the 
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brain parenchyma. In CE-T1w MRI, the T1 signal – a measurement of the early relaxation 
of protons in a magnetic field after a radiofrequency pulse, also known as spin-lattice 
relaxation - is used to define the image intensity for every voxel in the brain (7). Since 
gadolinium has a much higher T1 relaxivity compared to endogenous tissue, any 
gadolinium in the parenchyma will show up as bright enhancement on CE-T1w and can be 
used to detect regions of tumor with high specificity (8). A dose of 60 Gy is delivered to 
any residual enhancing tissue (after debulking of tumor), since these regions are known to 
be of high tumor burden. However, since gadolinium will only leak into to the tissue where 
the blood-brain barrier has been disrupted, CE-T1w MRI does not identify regions of tumor 
where the barrier is intact. Thus, a more sensitive imaging technique is used to guide a 
second prescription dose of radiation. 
A second tier of RT (typically 46-51 Gy) is delivered to areas of hyperintensity on 
T2-weighted fluid-attenuation inversion recovery (FLAIR) MRI (9). The T2-weighting of 
signal, also known as spin-spin relaxivity, is a measurement of the later relaxation of 
protons in a magnetic field after radiofrequency stimulation (7). A variety of possible tissue 
pathologies can lead to increases in the T2-weighted signal as measured by FLAIR: tumor, 
inflammation, or vasogenic edema (10). Thus, FLAIR provides a sensitive but not specific 
measure of tumor burden. 
Despite this high dose of RT and concurrent chemotherapy, patients often undergo 
disease progression (recurrence) at a median of 4 months after treatment (5). Recurrent 
glioblastoma is very difficult to treat, often being resistant to further radiation and 
inaccessible for secondary surgical resection (11); therefore, understanding why tumor 
recurs and trying to delay recurrence becomes a primary goal of glioblastoma research. 
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The location of recurrent disease can also vary largely: within the original 60 Gy RT target, 
within the intermediate dose area, or to regions several centimeters away, including 
crossing the midline (12). The latter of these suggests that there were regions of occult 
tumor which were not targeted for RT, and therefore able to continue proliferating. It is 
therefore necessary to find a better imaging modality that can identify the full extent of 
tumor so that these regions of occult tumor burden can be appropriately targeted for 
treatment. After all, what cannot be seen cannot be treated. 
1.2 Magnetic resonance spectroscopy 
Proton magnetic resonance spectroscopy (1H-MRS) is a modality that enables the in 
vivo measurement of several different chemicals, or metabolites, in tissue. Unlike proton 
MRI, which measures the bulk resonance signal of all protons in a magnetic field, MRS 
separates out the signals of protons from different chemicals. While protons have a specific 
resonance frequency in a magnetic field, 42.58 MHz / T, local electric fields around each 
proton due to the presence of electrons can slightly shift the resonance frequency on the 
order of tens of Hz. A proton that is in a relatively neutrally-charged environment, such as 
within the hydrocarbon chain of a lipid, will have a resonance frequency shift close to zero. 
n the other hand, protons next to lots of electrons, such as the two in each molecule of 
water, will have a larger shift. This chemical shift is described in the number parts per 
million (ppm), indicating the shift in Hz per MHz from the central resonance frequency; in 
this way, this unitless measure of chemical shift enables comparison across different field 
strengths. MRS can be performed on standard MR instrumentation, and a single-voxel 
implementation is available from most vendors. Figure 0.1 shows a sample single-voxel 
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MRS screenshot from a vendor-provided sequence. As shown, several cerebral metabolites 
can be detected using short-to-medium echo times at acquisition (13-15):  
 Choline-containing compounds (Cho, 3.2ppm) are associated with 
phospholipid metabolism and membrane synthesis; the Cho signal can be 
used as a surrogate measure of membrane turnover in proliferating cells; 
 Creatine (Cr, 3.0ppm and 3.9ppm) is an energy-carrying compound 
associated with ATP synthesis; 
 N-acetylaspartate (NAA, 2.0ppm and 4.4ppm) is a neuronal protein used in 
energy transfer and myelin metabolism found specifically in neurons; it is 
therefore used as a measure of neuronal health. 
 
 




1.2.1 Whole-brain spectroscopic MRI identifies occult tumor 
While MRS has been available for decades – predating MRI as we know it today 
(16) – the technology has only recently been adapted for imaging the whole-brain rather 
than measuring metabolite signal in a single voxel. The echo-planar spectroscopic imaging 
(EPSI) sequence created by Andrew Maudsley’s group at the University of Miami is one 
example of a modern MRS imaging sequence (17,18). EPSI uses a pulse-echo paradigm to 
measure multiple voxels simultaneously in a single slice; multiple slices are measured in 
series to produce a 3D volume. EPSI incorporated an interleaved water measurement in 
addition to the chemical shift measurements, which enables the normalization of each 
metabolite level to the water signal, thus yielding metabolite concentrations. The current 
implementation of EPSI on a 3T scanner produces a 64x64x32 matrix with a spatial 
resolution of 4.5x4.5x5.4mm, with an acquisition time of 15 minutes. During the same 
scanning session, a high-resolution (~1mm isotropic) T1w sequence is obtained. The T1w 
and metabolite measurements can then be co-registered into the same image space, 
allowing for metabolite overlays on the structural information provided by T1w MRI 
(Figure 0.2). This combination of high-resolution whole-brain MRS aligned with 
conventional imaging has been dubbed “spectroscopic magnetic resonance imaging” 
(sMRI) by Shim et. al. (19,20).  
sMRI has been shown to be useful in the detection of metabolite alterations in several 
brain pathologies, including tumors such as glioblastomas. In glioblastoma, the malignant 
glial cells proliferate rapidly and therefore have high membrane turnover; when compared 
to the relatively senescent neurons, this produces a detectable increase in choline 
metabolism; concurrently, the proliferation of glia leads to displacement and death of 
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neurons, resulting in a marked decrease in the levels of intracellular N-acetylaspartate 
(21,22). As shown in Figure 0.2, the regions of the brain with such altered metabolism can 
be mapped out using sMRI. Recently, our lab has shown that sMRI changes in these two 
metabolites and their ratio (Cho/NAA) can identify occult tumor beyond what is seen on 
standard imaging (20). In that work, Cordova et. al. scanned patients with glioblastoma 
using the EPSI sequence, then, at the time of resection, collected tissue samples from 
regions of elevated Cho/NAA. Some of these samples were within regions of enhancement 
on CE-T1w or hyperintensity on FLAIR imaging, but several were in regions that appeared 
“normal” on conventional imaging. However, all samples were found to contain at least 
some tumor cells in histology (as measured by staining with SOX2, a glioma-specific 
marker), and Cho/NAA was found to have a statistically significant correlation with the 




Figure 0.2: Spectroscopic MRI (sMRI) of a patient with glioblastoma. 
 
 Furthermore, Cordova et. al. showed that regions of Cho/NAA elevation that were 
occult on standard imaging – and thus not targeted for surgery or high-dose RT – correlated 
with the regions where disease first recurred. These landmark findings strongly suggest 
that sMRI can be a useful biomarker for identifying occult tumor, and could potentially be 
used to proactively modify where treatment is delivered to patients. 
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Figure 0.3: The Cho/NAA ratio can identify occult regions of GBM infiltration. Two cases 
are shown; (a) CE-T1w MRI taken pre-RT reveals enhancing tumor only, while (b) 
concurrent sMRI reveals elevated Cho/NAA abnormalities beyond enhancing lesions; (c) 
a CE-T1w MRI taken 4 weeks post-RT reveals tumor growth along both sMRI 
abnormalities. Adapted from Cordova et. al., Neuro-Oncology (2016).  
 
 
1.3 Current Challenges for sMRI 
While MRS has been shown to be useful in several neuropathologies, many technical 
challenges have prevented wide-spread adoption of this technique. While research is 
actively being pursued on improving MRS acquisitions, this section will focus on post-
acquisition processing since that is most relevant to the work in this dissertation, and is of 
particular importance to whole-brain MRS.  
1.3.1 Spectral Fitting 
 11
As with other MRI sequences, the signals collected from scanner consist of field 
induction decays (FIDs) as different parts of k-space are acquired. These FIDs are 
composed of several sinuosoidal components oscillating at the resonance frequencies of 
the protons they represent. Once these FIDs are acquired, they are converted into the 
frequency domain via Fourier transform as seen in Figure 0.1. The next step is to quantify 
the metabolites present within the spectrum by applying known models of spectral shape 
to the acquired data, and is often referred to as “spectral quantitation”, “spectral analysis”, 
or “spectral fitting”.  
A common model for describing the shape of proton resonance in a magnetic field 
is the Lorentzian-Gaussian function (23). In the time domain, the function describes a 
dampened oscillation at a given frequency, while in the frequency domain it describes a 
single resonance peak centered on the same frequency. There are six parameters for the 
Lorentzian-Gaussian function: frequency, amplitude, zero- and first-order phase, and two 
linewidth coefficients representing the combination of Lorentzian and Gaussian 
dampening. Variations on this model include using just a Gaussian or Lorentzian shape, or 
the Voigt profile (24). Algorithms which model a spectrum as a combination of individual 
peak resonances are referred to, appropriately, as “peak fitting” algorithms. The AMARES 
(advanced method for accurate, robust, and efficient spectral fitting) software is an example 
of one system that performs peak fitting in this manner in the time domain (25). 
Since many metabolites contain multiple protons, the MRS of a metabolite may 
consist of multiple Lorentzian-Gaussian resonances, referred to as “multiplets”. 
Mathematically, a basis set can be established for each metabolite consisting of a 
combination of known multiplet parameters. For single-voxel MRS, the gold standard 
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software for spectral fitting is LCModel, a software package developed by Stephen 
Provencher in 2001 that utilizes basis sets to model spectra (26). By modelling all the 
resonances present in a spectrum, it is possible for LCModel to fully parameterize the 
spectrum. However, challenges arise when certain chemicals are present in very low 
concentrations or when resonance peaks overlap. 
Other algorithms seek to only use spectral shape models for metabolites of interest 
and separately model the “background” or “baseline” signal of the spectrum. The 
quantitation based on semi‐parametric quantum estimation (QUEST) algorithm operates 
on time-domain spectra using the Lorentizan-Gaussian lineshape for metabolites and 
applies singular value decomposition (SVD) to model the smooth components of the 
baseline signal (27). More recently, the Totally Automatic Robust Quantitation in NMR 
(TARQUIN) algorithm utilizes Hankel SVD to remove the water signal from spectra, 
thereby reducing much of the background signal, and a non-linear least squares method for 
separating out metabolite basis sets (28). For whole-brain sMRI obtained using the EPSI 
sequence, the FITT program of the Metabolite Imaging and Data Analysis System 
(MIDAS) operates on frequency-domain spectra and uses Lorentzian-Gaussian models for 
the peak components of a spectrum, and some sort of smooth function such as splines or 
wavelet reconstruction for the baseline (29,30). Liang et. al. expanded the idea of a basis 
set as a set of metabolite resonances to a set of tissue distributions containing multiple 
metabolite each (referred to in their work as “subspaces”); e.g. – a basis set could include 
a priori knowledge of the observed spectra for “normal neurons”, “glioblastoma”, and 
“lipid” (31). 
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In each of these algorithms, a common theme is the need for iterative processes 
such as expectation-maximization or the Levenberg-Marquardt algorithm to decompose 
the spectra into its constituent parts. These algorithms have a tradeoff between 
computational time and accuracy: an increased number of iterations are more likely to lead 
to convergence, assuming the models selected for spectral shape and background signal are 
appropriate. In general, these iterative approaches cannot be easily parallelized, and so 
while software such as LCModel are excellent for single and multi-voxel spectroscopy, 
they do not scale efficiently for whole-brain spectroscopy. MIDAS, which is a commonly 
used software for data acquired using EPSI, can take 40-60 minutes (even with powerful 
multi-threaded hardware) to perform spectral fitting on a single study, placing a practical 
constraint on implementation of this technology in the clinical workflow. 
1.3.2 Inter-subject Comparison 
MRS by its nature is not directly measuring metabolite concentrations but rather 
the radiofrequency (RF) signal of excited protons returning to their ground state. While 
this is correlated with concentration, the only way to get true concentrations is to calibrate 
to some reference signal with known concentrations. This can be done via an external 
phantom (and adjusted for partial volume within voxels and for the load on the 
excitation/receiver RF coils) (32,33), or by normalizing metabolite signals with the 
intracellular water signal (34). The latter technique, which is also implemented in MIDAS 
when using the EPSI sequence, relies on published reference values for the water content 
of voxels in T1-weighted MRI. Thus, absolute concentrations generated using this 
methodology do not have molar units, but rather are referred to (in MIDAS) as 
“institutional units”; this means that different studies obtained on the same instrumentation 
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are comparable, but not necessarily comparable for subjects scanned on different hardware 
(18). Metabolite ratios, by virtue of being unitless, are comparable across subjects 
regardless of instrumentation. 
While normalization via intracellular water and metabolite ratios allow comparison 
of voxel values between subjects, there is still the issue of inter-subject variability that 
needs to be taken into count before one can identify voxels as being “within normal limits” 
or abnormal. Metabolite values are known to vary based on location within the brain 
(17,35), on subject age (36,37), in the presence of global inflammation (38), and even in 
healthy tissue when there is pathology elsewhere in the brain (39-41). A common method 
for internally normalizing a subject’s metabolite map is to divide all voxels by the mean 
metabolite value in normal-appearing white matter (NAWM), a region defined 
radiologically as white matter tissue in the hemisphere of the brain without pathology. This 
technique is used to generate several advanced metrics for MRS, such as the choline-to-
NAA index (42) and the Cho/NAA abnormality index (also called “relative Cho/NAA”) 
(20). It is the Cho/NAA abnormality index that was found by Cordova et. al. to be the most 
correlated with histological presence of tumor cells, as described previously. The NAWM 
is typically defined by neuroradiologist segmentation, a process which is time intensive 
and requires manual intervention by a physician. Thus, to improve the clinical use of 
MRS/sMRI using internal normalization, improved algorithms that do not require manual 
segmentation are needed. At the time of writing, the MIDAS software suite has a beta 
version of automated NAWM segmentation based on clustering of tissue into grey matter, 
white matter, and cerebrospinal fluid. 
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1.3.3 Quality Analysis 
In MRS and particularly in whole-brain spectroscopic imaging, the imaging field-of-
view can consist of several thousand spectra. Quality analysis (QA), also known as artifact 
detection, describes the process of systematically identifying spectra that are artifactual – 
of poor quality – such that accurate quantitation cannot be determined from them and they 
should be excluded from any clinical decision making. In a 2004 review article, Kreis 
performed a systematic review of the types of artifacts that commonly affect MRS, 
including poor signal-to-noise, motion correction, lineshape distortions, partial volume, 
Eddy currents, insufficient water or lipid suppression, and errors in software processing 
(43). While this review was written primarily for single voxel and multivoxel MRS, whole-
brain sMRI is perhaps even more sensitive to some of them. For example, during 
acquisition, shimming is performed to try and smooth out any magnetic field 
inhomogeneities which can lead to off-resonance signals; but with the large volume of and 
the heterogenous tissues within the field-of-view in whole-brain scans, inhomogeneities 
tend to play a larger role. 
Manual inspection is still considered the gold standard for identifying poor quality 
spectra (43), though several algorithms for quality analysis have been developed to 
systematically identify poor quality spectra without expert review. This is critically 
important for whole-brain spectroscopy, where manual inspection of thousands of spectra 
is impractical. The first type of QA algorithm operates directly on the acquired data and 
assess statistical metrics such as magnitude of spectra or metrics of variability (e.g. 
kurtosis) (44). These metrics have the advantage that they are agnostic to the performance 
of spectral quantitation algorithms and can remove the most egregious artifacts such as 
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voxels obtained within areas of necrosis or outside the brain, but are not sensitive enough 
to identify other types of artifacts. The most common set of QA algorithms rely on metrics 
of spectral quantitation, such as the linewidth of peaks, the Cramer-Rao bounds of the fit, 
or the root-mean-squared error (RMSE) of the fit (30,45). These algorithms are more 
sensitive since they incorporate information from known spectral models and can therefore 
identify when the acquired signals deviate from the expected model; however, because they 
are dependent upon spectral quantitation, any errors in spectral processing can lead to 
erroneous identification of artifacts during QA. A third class of QA algorithm utilizes 
machine learning techniques to automatically classify spectra as being of “good” or “poor” 
quality; these techniques are described in the next sections. 
 
1.4 Machine Learning 
In traditional computational techniques, programmers will write code to perform 
specific operation on an input data set in order to produce some meaningful output. 
Machine learning is a broad term used to describe a variety of statistical and computational 
techniques that seek to learn what those specific operations should be; in other words, both 
the input and output are known, but the relationship between them needs to be learned. In 
general, there are two types of machine learning techniques that can be applied to tasks 
such as input classification – supervised and unsupervised techniques (46). Supervision 
refers to how a machine learning algorithm is trained, e.g. is it guided by known output 
(supervised), or can the output be inferred from some properties of the input 
(unsupervised). While machine learning encompasses a large field of study, in this work 
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we focus specifically on a type of system known as the neural network. Neural networks 
are most often trained using a supervised technique, and the rest of this section assumes 
this paradigm; in Chapter 4, additional discussion will be presented on how neural 
networks can be trained in an unsupervised fashion for a specific type of task. 
Neural networks, also known as artificial neural networks (ANNs), are systems of 
linear operations designed to have plasticity, or the ability to update themselves via by 
analysing their inputs and outputs, so-called because of their similarity to how the brain 
works (in a simplified fashion) (47). ANNs are composed of nodes called neurons; each 
neuron receives input signals from one or more neurons, combines these inputs together, 
and if it reaches some activation threshold, passed an output signal to other neurons. By 
combining thousands of inter-connected neurons in this fashion, complicated non-linear 
functions can be approximated by the simple linear combination of signals. The ANN will 
undergo “training,” wherein the network is presented with some input and the expected 
output. Mathematical operations such as gradient backpropagation can be used to tune each 
node – which other nodes it should receive input from, how much weight it should give to 
each input signal, and what its activation threshold should be – such that the network can 
turn the input into the expected output. Over time and many input-output pairs, the network 
will eventually converge into a steady-state wherein it can reproduce all input-output pairs 
in the training data set. With a sufficiently large training set and sufficiently large number 
of neurons, it is possible for an ANN to learn any possible input-output relationship. 
However, this comes at a large computational cost, with the number of possible inter-
neuron connections increasing exponentially with the number of neurons in a network, and 
gradient backpropagation needing to be calculated for each connection. ANNs were an area 
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of active research for decades – a Google Scholar search reveals over 231,000 published 
articles from 1980 to 2010 containing “artificial neural network” – but these were limited 
by the computational resources available. Two main advances have driven more recent 
research in neural networks. The first is a drastic increase in computational power that 
occurred in the 2010s with the rise of commodity graphical processing units (GPUs), 
processors that were designed initially for computer graphics but contained hundreds of 
independent processing cores that could run backpropagation in parallel. The second is the 
development of the convolutional neural network (CNN), which rely on the fact that input 
data typically have some structure (e.g. images) and so the fully density of ANN 
connections is not necessary to capture this structure (48). Instead, kernels of much smaller 
size than the input can be convolved with input data in order to extract certain features 
from the data. In a CNN, input data are passed through several “layers” of convolution (and 
potentially some other layers such as traditional ANNs) to generate an output; during 
training of the CNN, the values of the kernels are updated. Thus, instead of needing an 
exponentially increasing number of inter-neuron connections as the number of neurons 
increases, in a CNN, the increase in complexity is approximately linear with the number of 
layers. With increasing computational resources such as GPUs and the ability to build more 
complex models, “deep learning” (referring to the increasing number of layers that data are 
passed through) has become a burgeoning area of academic research. Deep learning 
networks have shattered the performance benchmarks against both deterministic models 
and older machine learning techniques in many fields, from natural language processing to 
DNA mutation analysis to playing video games (49,50). While much of the initial work in 
machine learning was focused on everyday imaging, medical imaging can also benefit 
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greatly from these advances. Deep learning has also recently been shown to be a powerful 
method for extracting complicated feature sets from medical images (including MRI) in a 
fully automated fashion (51,52).  
In both supervised and unsupervised training of neural networks, there is some 
information is provided to the network a priori and other information that must be inferred 
by the network. The terminology for this is often referred to as the “input feature vector” 
or “input features”. Depending on the problem at hand, it may be beneficial to put in more 
or less data into the feature vector with the following qualification – the choice of features 
biases the network. For example, in a classification task based on medical images, the 
simplest approach would be to just provide the images as input and let the network try and 
extract all salient information. However, additional data can be input as additional features, 
such as statistical properties of the image or information about the subject whose image it 
is; the network no longer needs to infer these features and can instead use them directly in 
decision making. However, the network is now biased to rely on these features instead of 
determining computationally what are the best inherent features of the image. In practice, 
information should generally be provided if it is desirable to bias the network in a particular 
fashion. This is task of feature engineering – selecting what features should be input into 
the network based on knowledge of the task at hand. In Chapter 2, a CNN is developed for 
spectral artifact filtering that explicitly incorporates some information about the resonances 
of MRS but not any features that were generated by other algorithms (e.g. a specific 
spectral fitting algorithm). In this way, some knowledge about the fundamental properties 
of MRS can be used to bias the network, but the network is independent of other engineered 
features and can therefore be applied in the absence of those features (e.g. if a different 
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spectral fitting algorithm is used). Similarly, in Chapter 4, an unsupervised training 
architecture is developed that explicitly incorporates knowledge about the shape of spectral 
peaks, forcing the network to be confined to those spectral shapes.  
 
1.5 Machine Learning for Magnetic Resonance Spectroscopy 
In recent years, several MRS groups have adapted machine learning techniques for 
the imaging modality, focused primarily on acquisition (e.g. compressed sensing), spectral 
quantitation, and quality analysis. This section will cover the recent literature for the latter 
two foci as they are most relevant to this dissertation. 
1.5.1 Quality Analysis 
While the QA algorithms described previously can identify the majority of poor 
quality spectra (in our lab’s experience, perhaps 70-80% of all artifactual spectra), several 
artifacts remain and cause issues with visualization and target generation. Since manual 
inspection by MRS experts is considered the gold standard, a new set of QA algorithms 
seek to generate tools that can mimic the expert’s gestaltism. In 2008, Menze et. al. used 
random forest classifiers to separate high and low quality spectra per expert reviewers; of 
note, the feature vector used by the random forest was the magnitude of spectrum within a 
fixed resonance interval (44). That same year, Wright et. al. using independent component 
analysis to decompose spectra into several features, which were then fed into a support 
vector machine trained with expert classifications of spectral quality (53). Pedrosa de 
Barros et. Al. showed excellent performance for a spectral classifier based on a random 
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forest trained using manually generated features from both the time and frequency domain 
signals as input – peak SNRs, non-peak SNRs, and first- and second-order statistics 
(54,55). Finally, Kyathanahally et. al. demonstrated near-perfect removal of a single type 
of artifact – ghosting, the presence of spurious echos leading to off-resonance peaks – using 
convolutional neural networks (56,57). Collectively, these projects have shown that 
machine learning can indeed be useful in artifact detection for MRS, but also that there is 
much work to be done. Specifically, machine learning has not been applied to whole-brain 
data collected using the EPSI sequence. 
1.5.2 Spectral Fitting 
As described in Section 1.3.1, spectral fitting can be a computationally intensive 
task and is prone to errors when signal quality is poor or in the presence of artifacts. While 
there is a plethora of research in the use of various optimization techniques to improve 
spectral fitting, there has been limited work to date on the application of machine learning 
techniques to this task (see Table 0.1 for a summary). 
In general, there have been two tasks that this body of work has tried to solve: 
determination of metabolite concentrations (relative concentrations), or actual fittings that 
include a model of the baseline and each metabolite. Hiltunen et. al. used an ANN in 2002 
and trained it to automatically determine the metabolite concentrations of single in vivo 
spectra from patients with gliomas, and observed ANN performance to be comparable to 
that produced by lineshape fitting models (58). In 2006, Bhat et. al. also used an ANN 
architecture, but to actually model peaks using Lorentzian-Gaussian functions rather than 
predicting metabolite areas (59). Thus, their model was firmly contextualized within the 
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constraints of resonance physics. However, it was limited in that it required the baseline 
signal to be removed by other means, and for the specific bounds of the peak signal to be 
identified. More recently, Das et. al. created two separate architectures – one based on a 
random forest and the other using a multilayer perceptron (MLP, a type of multilayer ANN) 
– predict metabolite concentrations on 2D MRSI data sets (60,61). They observed 
performance comparable with the gold-standard LCModel software, but in a fraction of the 
time. To date, however, no machine learning model has been published that can provide 
full spectral fittings (e.g. constraining to spectral lineshape models) that include a model 
of the baseline signal and any phase shifting that may be present. Such a model will be 
necessary if it were to replace existing software such as LCModel, jMRUI, or MIDAS. 
 
Table 0.1: Summary of literature on machine learning for spectral fitting 
Author Data Technique Training Output 
Hiltunen, 2002 
(58) 












Unsupervised Fitted spectra 
Das, 2017 (60) Simulated and 
in vivo 2D 
spectra 
Random forest LCModel Metabolite 
concentrations 
Das, 2018 (61) Simulated and 







1.6 Specific Aims 
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While sMRI has been well established in the research arena, the clinical adoption of 
the technology has been limited due to several technical challenges. While the EPSI 
sequence has reduced acquisition times to a reasonable 15 minutes, post-processing of the 
data from the scanner into metabolite heatmaps showing in Figure 0.2 and Figure 0.3 
requires several computationally-intensive steps. The presence of spectral artifacts – 
erroneously calculated metabolite concentrations due to magnetic field inhomogeneities – 
remain a concern for accurate volumetry, which is especially important if sMRI is to be 
used for treatment planning (43). Due to the complexity of its data, sMRI volumes cannot 
be visualized or analyzed using standard clinical imaging tools, and thus the incorporation 
of this information into the clinical workflow is limited. Finally, there are known variations 
in basal metabolism between patients, and this inter-patient variability needs to be 
addressed when determining practice guidelines for sMRI. 
To address challenges, we have developed a software framework that incorporates 
the latest knowledge of machine learning and high-performance computing to bridge the 
gap in the clinical utilization of sMRI for radiation therapy guidance.  
Aim 1: Develop preprocessing algorithms for spectral quality filtering using deep 
learning. Using deep learning, we will develop a spectral quality filter to remove aberrant 
spectra from sMRI volumes. We will develop an easy-to-use, web-based platform to allow 
MR spectroscopy experts to crowd-source “ground truth” data of spectral quality – a highly 
subjective metric – and use these data to train a neural network which can be applied to 
whole-brain sMRI volumes. 
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Aim 2: Develop normalization methods for personalized spectroscopic MR imaging 
of glioblastoma. To account for basal variations in metabolic levels, we will develop an 
automated and personalized normalization scheme for sMRI of patients with glioblastoma. 
The normalization scheme will be implemented based on an Gaussian mixture model 
optimized using expectation-maximization.  
Aim 3: Develop a software framework capable of incorporating sMRI into the 
clinical workflow. To enable the use of sMRI in the clinical mainstream, we will develop 
a web-based application that will allow MR technicians to import raw spectroscopic data 
from an MR scanner and automatically produce clinically relevant 3D metabolite (and 
ratio) maps, and radiation therapy (RT) or surgical target volumes after co-registration with 
clinical anatomical MRI. This will serve as a platform for integrating algorithms in our 
research, such as the quality filter and normalization algorithm developed in Aims 1-2, and 
for coordinating multi-center clinical trials.  
Aim 4: Improve efficiency of spectral fitting using a parametric deep learning model. 
Spectral fitting, the process of parameterized curve fitting on a raw spectrum, enables 
quantification of relative metabolite concentrations. Current algorithms are based on 
iterative optimization of the spectral baseline and peak models and can require upwards of 
an hour per 3D whole-brain scan, limiting the utility of sMRI in the immediate clinical 
setting. We will develop a single-pass neural network capable of operating in parallel on 
thousands of spectra to perform rapid fitting of spectra. We will develop an unsupervised 
learning architecture that incorporates models of spectral lineshape and baseline such that 
the resulting spectral fitting is fully constrained within known physics. 
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Proton spectroscopic magnetic resonance imaging (sMRI) is a non-invasive modality 
capable of generating volumetric maps of in vivo tissue metabolism without the need for 
ionizing radiation or injected contrast agent. sMRI has been shown to be a viable imaging 
modality for studying several neuropathologies. However, a key hurdle in the clinical 
adoption of sMRI is the presence of spectral artifacts that can arise from a number of 
sources, possibly leading to false identification of lesions. 
1.8.2 Methods 
A deep learning model was developed that was capable of identifying and filtering out poor 
quality spectra. The core of the model used a tiled convolutional neural network (CNN) 
that analyzed frequency-domain spectra to detect artifacts. 
1.8.3 Results 
When compared to a panel of spectroscopy experts, our CNN achieved high sensitivity and 
specificity with an area under the curve of 0.95. A visualization scheme was implemented 
to better understand how the CNN made its judgement on individual spectra, and the CNN 




The fully-automated method for assessment of spectral quality provides a valuable tool to 




Proton magnetic resonance spectroscopy imaging (sMRI) is a quantitative imaging 
modality that measures endogenous metabolite concentrations in vivo (22,62). Recent 
advances in sMRI protocols, such as the development of the 3D echo-planar spectroscopic 
imaging (EPSI) sequence and improved post-processing methods have enabled whole-
brain acquisition with spatial resolutions on the order of one centimeter, thereby improving 
the utility for diagnostic and treatment planning applications (17,18,20,63).  Three 
metabolites of key importance in the evaluation of patients with glioblastoma, specifically 
choline (Cho), N-acetylaspartate (NAA), and the Cho/NAA ratio. The Cho/NAA ratio is 
widely used for depiction of tumor volumes and infiltration due to increased contrast as a 
result of the opposite changes of these metabolites in the tumor (20). A key challenge to 
the analysis and interpretation of sMRI volumes is the presence of artifacts due to poor 
spectral quality (64). Artifacts arise from magnetic field inhomogeneities, subject 
movement, or improper water and lipid suppression, yielding reduced peak signal-to-noise 
ratios and distorted and broadened line shapes that lead to difficulties in quantification of 
the metabolite peaks (30,64). Visually, artifacts may appear as foci of hyper- or hypo-
intense signal (Figure 0.1), which can lead to false interpretation. For treatment planning 
purposes, it is especially important to obtain accurate volumetry of target pathology. 
Currently, confirmation of true metabolic abnormality requires manual review of spectra 
by experts. However, with several thousand spectra in a single whole-brain volume, manual 
review is impractical. To adopt whole-brain sMRI into the clinical workflow, it is therefore 
necessary to develop automated methods for assessment of spectral quality.  
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Figure 0.1: Sample gallery of sMRI spectra. Artifacts in spectroscopic MRI (sMRI) arise 
due to several causes, and can lead to false interpretation of pathology. (A) Healthy tissue 
shows a relatively low choline to N-acetylaspartate ratio (Cho/NAA), whereas (B) tumor 
shows an elevated ratio, appearing as hyperintense on a Cho/NAA map. Artifacts can arise 
in tissue boundaries and in areas with poor lipid or water suppression, and can result in 
either (C) hyperintense lesions or (D) dropout of signal. Accurate volumetry of pathology 
is critical if sMRI is to be used for treatment planning.  
 
 
Several approaches have been developed to filter poor quality spectra from sMRI 
datasets, including exclusion criteria based on peak linewidths (17), reliability testing (65), 
Cramer-Rao bounds (45), and machine-learning techniques such as random forest 
classifiers (44,54). In each of these algorithms, the classification of spectral quality is based 
on a collection of “engineered” features as input; these features are categorical or ordinal 
vectors that seek to summarize the information encoded in each spectrum. Some features 
are derived directly from the raw data, such as the magnitude of each point in the spectrum 
or statistical metrics of variability (e.g. kurtosis, skewness) (44), or derived from analysis 
of spectral fitting, such as singlet linewidths and Cramer-Rao bounds. Common to all these 
approaches is that the definition of features is required prior to performing any analysis. 
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Thus, these features capture criteria that MR experts explicitly believe are important to 
spectral quality, and machine learning algorithms built using these engineered features 
have shown promise as spectral quality filters (44,54,66). In contrast to systems that model 
expert beliefs explicitly, deep learning broadly defines a category of machine learning 
algorithms that can learn underlying features from raw data without the need for any a 
priori definition of such features, and have been able to shatter benchmarks in natural 
language processing, medical image segmentation, survival analysis, and identification of 
pathology in medical images (67-71). Deep convolutional neural networks (CNNs) in 
particular are well suited to analyzing waveforms similar to raw spectra (72,73), and have 
only recently been applied in the context of MR spectroscopy (56). CNNs consist of 
sequential layers of convolution, downsampling, and logistic regression that ultimately 
learn the underlying features of the data that lead to a desired endpoint, in this case whether 
or not a spectrum is suitable for analysis. Training a CNN involves updating the 
coefficients of the convolutional layers to reach the endpoint. However, designing the 
architecture of a CNN – e.g. the number of layers and the size of the convolution kernels – 
often relies on trial and error. A new framework to determine optimal architecture 
parameters is known as Bayesian optimization, which performs non-linear optimization 
without the need for defined derivatives (74). 
In this work, a CNN was developed to learn whether or not a spectrum has sufficient 
quality to be used for clinical assessment. A state-of-the-art Bayesian optimization 
technique was used to automatically tune the network architecture and train the network 
on data from patients with glioblastoma. A framework is provided that enables users to 
visualize the rationale behind the CNN’s classification of individual spectra. Finally, a 
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1.10.1 Image Acquisition and Processing 
sMRI data were available from a database of patients with glioblastoma previously 
enrolled in a phase II clinical trial (75) who received post-surgical scans. All scans were 
conducted in a 3T MRI scanner with a 32-channel head coil (Siemens Medical) and were 
obtained following surgical resection but prior to the start of radiation therapy and 
chemotherapy. Anatomic volumes obtained used a T1-weighted (T1w) magnetization-
prepared rapid gradient echo pulse sequence (TR = 1900 ms, TE = 3.52 ms, 256 x 256 
matrix, flip angle (FA) = 9°). A whole-brain 3D echo-planar spectroscopic imaging 
sequence (EPSI, TR = 1551 ms, TE = 17.6 ms, FA = 71°, final matrix size of 64 x 64 x 
32) yielding a final voxel volume of 1.5 cm3, was obtained during the same scanning 
session. Both sequences were obtained at a +15 degree tilt in the sagittal plane from the 
anterior commissure-posterior commissure line in order to capture the entire cerebrum 
while minimizing acquisition in the clivus, sinuses, and retro-orbital fat. An oblique 
saturation band was placed in the sagittal plane from the optic chiasm to the cerebellum to 
suppress signal from those regions. Image reconstruction and formation of metabolite 
images were carried out using the Metabolite Imaging and Data Analysis System (MIDAS) 
package (17,18). Briefly, this processing includes spatial reconstruction, frequency 
alignment, B0 field correction, co-registration of the T1w and EPSI volumes, registration 
 32
of the T1w volume to an anatomic atlas, lipid suppression, spectral fitting, and 
normalization with internal water signal to produce relative concentrations of metabolites. 
Additionally, pre-filtering of data using algorithms built into MIDAS were applied to all 
data to replicate the workflow currently used in clinical studies. First, a mask based on an 
anatomic atlas was applied to exclude voxels outside of the brain, which drastically reduces 
the number of voxels to be analyzed. Voxels with a water linewidth > 18 Hz, as calculated 
from T2 decay, were removed prior to spectral fitting to save computation time.  After 
fitting, voxels with a metabolite linewidth > 18 Hz were also removed; this step served as 
an initial filter to remove spectra known to be of poor quality prior to visual review. A 
representative volume contained 10,298 voxels after filtering, however, since the data is 
also interpolated and smoothed in each dimension during reconstruction it is estimated that 
approximately 1,280 independent spectra remain within the brain volume. Spectra were 
then randomly sampled from a grid with a skip factor of 2, including both regions of tumor 
and healthy tissue, and exported for analysis. A total of 8,894 spectra collected from 9 
patients with glioblastoma were collected. 
1.10.2 Data Labelling and Consensus 
A custom web platform for multi-rater annotation of spectral quality was developed 
and used to label the exported spectra for training and testing the artifact detection network. 
Online Spectroscopic Classification and Review (OSCAR) was written in PHP – a 
language for server-side scripting of webpages – and enables multiple MR spectroscopy 
experts to visualize and review spectra, as seen in Figure 0.2. Each expert is presented with 
a random subset of spectra and shown the chemical-shift spectrum along with a cross-
haired T1-weighted MR image depicting the spectrum’s anatomic location. The user 
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Figure 0.2: A web interface for MRS expert ratings. To collect ground truth data for 
machine learning classifiers based on spectral quality, we developed a web-based interface 
for MR experts to use.  
 
 
Each spectrum was presented to three randomly chosen users from a pool of experts 
(authors AAM, JSC, BJS, HP, GV, PBB, and HS) so that an expert consensus could be 
measured; a total of 8,894 spectra were classified in triplicate. Consensus was based on a 
majority vote decision rule; if all three voted differently or if there was a large discrepancy 
in votes (e.g. 2 “Good” and 1 “Poor” or vice versa), the spectrum was discarded. Table 0.1 
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includes the results of labeling and consensus; a total of 427 spectra (4.8%) were discarded 
due to large discrepancy amongst experts. The consensus labels of “Good” and 
“Acceptable” were merged together into a singular “Good” class, yielding a class 
proportion of 72% “Good” and 28% “Poor”. The final set of 8,467 spectra were then 




Table 0.1: Consensus rating of spectral quality by a panel of MRS experts.  
Reviewer Labels Consensus Label # of Spectra % of Total 
G G G Good 360 4.05 
G G A Good 914 10.28 
G A A Acceptable 1597 17.96 
A A A Acceptable 1672 18.80 
A A P Acceptable 1448 16.28 
A P P Poor 1120 12.59 
P P P Poor 1356 15.25 
G G P Discarded 23 0.26 
G A P Discarded 355 3.99 
G P P Discarded 49 0.55 
      
   Total Spectra: 8894  
   Spectra discarded: 427 4.80 
   Final data set: 8467 95.20 
   Training set: 6767  
   Validation set: 850  




1.10.3 Network Architecture 
A CNN for spectral quality was developed using the TensorFlow (Google, Inc.) 
framework on a Windows workstation with two Titan X graphical processing units (GPUs). 
GPUs are highly optimized for parallel computations and enable rapid development of 
neural networks. A high-level overview schematic of the CNN is displayed in Figure 0.3a. 
It takes the 512-point real component of a spectrum as input. First, the spectrum is 
normalized to values between 0.0 and 1.0; for this step, a histogram of amplitudes of all 
spectra in the training data set was computed, and the 1st and 99th percentile values were 
used as the normalizing bounds. Using these bounds, all spectra are normalized to the same 
scale. The normalized spectrum is then split into six regions, called “tiles”. Three of these 
tiles were based on the known location of resonance peaks for the three largest metabolite 
peaks present: Cho (3.2 ppm), Cr (3.0 ppm), and NAA (2.0 ppm). Given the short TE that 
the data were acquired at, these three tiles are primarily composted of a Lorentzian-
Gaussian singlet as opposed to the slowly-changing spectral baseline and smaller overlaid 
macromolecule singlets found in other tiles (30). Since these tiles have different shapes, 
the tiled architecture effectively enables six parallel networks to be trained synchronously. 
Each tile is passed through a series of convolutional and max-pooling layers. Layers 1 and 
2 each perform 32 convolutions on the data, and layers 3-7 each perform 64 convolutions. 
Since CNNs operate best on low-amplitude data, outputs from each convolution are passed 
through a parametric rectified linear unit (PReLU), which restricts output range (76). Max-
pooling downsamples the output of each convolution by a factor of two, reducing the size 
of the data going into the next layer. After these 7 layers, outputs from each of the six tiles 
are concatenated together and passed through two fully-connected layers of 128 nodes. 
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Finally, logistic regression and softmax (77) operations are performed to yield a single 
scalar output within the range [0.0, 1.0]. The CNN is trained so that this output is the 




Figure 0.3: Schema of the spectral quality CNN and its training process. (a) A high-level 
overview of the convolutional neural network for spectral quality analysis. Input spectra 
are split into six tiles and passed through a series of convolution (*) and max-pooling (MP) 
layers, then concatenated and passed through fully connected layers to generate a scalar 
output of spectral quality. (b) Bayesian optimization is used to iteratively optimize 
architecture hyperparameters.  
 
 
Training the CNN involves optimizing the coefficients of all the convolution 
kernels and fully-connected nodes so that the output matches the consensus of the training 
data generated in OSCAR. If the consensus output was “Good”, the spectrum is given a 
class label of 1, and if the consensus output was “Poor”, the spectrum is given a class label 
of 0. The cost function to be minimized by a first-order optimizer is defined as the cross-
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entropy error of the class label and the output probability of the CNN (78). Spectra are 
passed in batches of 250 spectra through the network and the cost function is computed; 
gradient backpropagation then adjusts the network coefficients. For each batch, spectral 
from the training data set are randomly sampled without replacement; an epoch is defined 
as one full pass-through of the training set. After each epoch, a receiver-operator 
characteristic (ROC) curve is computed on the validation (n=850) sets, and the area under 
the curve (AUC) is reported. Training continued through many epochs until the AUC of 
the validation set converges. 
1.10.4 Bayesian Optimization 
CNN architecture hyperparameters, e.g. the number of layers in the CNN and the 
size of the convolution kernels, can have a large impact on performance. These 
hyperparameters cannot be defined by linear mathematical functions and therefore do not 
have explicit derivatives to be used for gradient backpropagation. Because of this, they are 
outside the scope of neural network training and are often defined by manual trial and error, 
which can be both time-consuming and highly subjective. Bayesian optimization is a 
statistical technique that models the performance of an algorithm using Gaussian processes 
and iteratively seeks to optimize performance over the space of possible algorithm designs 
(74,79,80). CNNs can be treated as a complex mathematical function with some unknown 
underlying statistical model. Bayesian optimization assumes a series of Gaussian 
distributions can reproduce the underlying model and uses those to indirectly optimize the 
CNN; this technique has previously been successfully applied to tune architecture 
hyperparameters (71,74). A Bayesian optimization approach using the Spearmint 
framework is used in this work to tune the size of the convolution kernels and the dropout 
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fraction of the fully connected layers (74). The variable to be minimized for Bayesian 
optimization is defined as the converged AUC of the validation data set as described in the 
previous section (Figure 0.3b). 
1.10.5 Gradient-weighted Class Activation Mapping 
While deep learning algorithms such as CNNs extract predictive features from input 
data, these features do not have any semantic meaning, and it is not readily apparent how 
to interpret them in a manner similar to feature ranking by standard statistical techniques. 
A recent method known as gradient-weighted class activation mapping (GradCAM) 
attempts to visualize which components of a specific input contribute to that input’s 
classification. GradCAM performs a gradient backpropagation from the output score to the 
final layer of convolution, which contains the highest level features detected by the network 
(81). These can then be visualized as heat maps over the original input, highlighting which 
components contributed most to the CNN’s decision. While this cannot be generalized to 
all input, it enables insight into what the network is doing. We implemented GradCAM for 
spectral data in TensorFlow. 
 
1.11 Results 
1.11.1 Training and Validation 
The CNN was trained over multiple epochs (complete passes through the training set) 
until the validation AUC achieved its peak value, an indication that additional training 
would result in overfitting. The Bayesian optimization framework was programmed to 
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maximize the peak validation AUC, and this along with a 2x2 contingency table (82) was 
reported for each parameter set. The final tuned parameters reported by Spearmint were 
the CNN learning rate and convolution kernel size. After Bayesian optimization was 
complete, the unused test set (n=850 spectra) was run through inference and probabilities 
were compared with reviewer labels to generate the final ROC curve shown in Figure 0.4a, 
with an AUC of 0.95. 
To compare the classifications of the CNN against each human expert’s classifications, 
an inter-rater agreement analysis was performed. A dissimilarity matrix, representing the 
percent disagreement between each pair of observers was calculated (Figure 0.4b). 
Multidimensional scaling a technique that transforms these pairwise distances into a two-
dimensional map to further visualize the relative agreement between pairs of raters, was 
performed (Figure 0.4c) for the seven human raters (H1-H7) and the CNN on the full data 
set. In a multidimensional scaling plot, points that are closer together represent higher 
agreement between the two raters’ decision on spectral quality. The geometric center of 
the human raters is also displayed on the plot. After training and tuning of the CNN were 
complete, it was run on the 427 spectra which the experts disagreed on, using a threshold 
of 0.7 on the CNN’s output probability for classification. A summary of the results is 
presented in Table 0.2; of note, the majority of these spectra were classified by the CNN 




Table 0.2: CNN classifications of the discordant data set. 
 CNN Classification CNN 
Probabilities 
Mean (std. dev.) Reviewer Labels # of Spectra Good Artifact 
G G P 23 23 0 0.998 (0.005) 
G A P 355 308 47 0.871 (0.261) 




Table 0.3: Feature vector generated by MIDAS used for training a random forest. 
Spatial Location Choline Peak Creatine Peak NAA Peak 
X coordinate Area Area Area 








    
Fit Parameters Quality Metrics Other Metrics  
Zero-order phase Residual error B0 Field Map  
First-order phase Chi-squared statistic Bias Field Map  




Figure 0.4: Spectra quality CNN performance versus MRS experts. (a) An unused test data 
set (n=850 spectra), with class proportions matching that of the full data set, was run 
through the CNN; comparing the output probabilities to ground truth resulted in a receiver-
operator characteristic curve with an AUC of 0.951. The (b) dissimilarity heatmap and (c) 
a multidimensional scaling plot comparing sets of pairwise inter-rater agreement show that 




To evaluate the relative performance of the CNN against traditional machine 
learning with engineered features, a random forest was generated using the same input and 
ground truth data using the Statistics and Machine Learning Toolbox in MATLAB R2016b 
(The MathWorks, Inc.). Twenty features generated by MIDAS during the fitting process 
were used (Table 0.3), and the model achieved an AUC of 0.948 after optimizing random 




Figure 0.5: Ranking of random forest feature vector by relevance. The MIDAS features 
used in the random forest classifier are ranked by their relative strengths in determining the 
forest’s classification decision. The random forest achieved an area-under-the-curve 




1.11.2 Gradient-weighted Class Activation Mapping 
Representative spectra are shown in Figure 0.6 with overlaid heat maps generated 
by GradCAM, revealing regions of the spectrum that contributed most to the CNN’s 
classification decision. Four representative spectra are shown, each with different causes 
leading to poor quality per the opinion of two of the expert spectroscopists. GradCAM 
highlights the regions of spectrum that correspond to those causes. To assess how the CNN 
makes a classification decision on good quality spectrum, an idealized “Good” spectrum is 
generated by taking the average of the amplitude all spectra classified as “Good” by the 
five readers (Figure 0.7), which increases the signal-to-noise ratio and reduces baseline 
variations. When GradCAM is run on this idealized spectrum, the heat map reveals that it 
is the regions outside of the metabolite resonance frequencies, e.g. the region of lipid and 




Figure 0.6: GradCAM analysis of representative poor quality spectra. Four spectra 
representative of the various phenomena that lead to artifacts were analyzed using 
GradCAM, a technique which produces a heat map of which portions of a specific input 
spectrum contributed most to the CNN’s final decision. The results show that the CNN is 
focusing on appropriate regions for each of these scenarios. Of note, when there is low 
signal-to-noise ratio due to partial volume effects at a tissue boundary (bottom left), nearly 





Figure 0.7: GradCAM analysis of an idealized good quality spectrum. An idealized “Good” 
spectrum, created by averaging all spectra classified as “Good,” shows that the CNN 
focuses most on the regions outside of the metabolic peaks for decision making. 
 
 
1.11.3 Whole-brain Pipeline 
A pipeline was developed for filtering spectral artifacts on whole-brain volumes. 
Briefly, all spectra were exported to a binary format able to be read by TensorFlow and 
tagged with their voxel locations for reconstruction. The trained CNN was then loaded and 
inference is performed on all voxels in a whole-brain volume; a probability of “Good” 
quality is exported and reconstructed into a 3D volume representing probability. A 
threshold on this probability can then be selected and applied to all metabolite voxels, 
eliminating those below it from the map; a threshold of 0.70 was selected for the whole-
brain images depicted here. Figure 0.8 shows a sample pre-radiation therapy Cho/NAA 
volume from a patient with a newly diagnosed left frontal glioblastoma following surgical 
resection of the tumor. Voxels with broad linewidths were already removed during data 
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processing in MIDAS with an initial filter based on water and metabolite linewidths. 
Cho/NAA elevation is observed posterior and medial to the surgical cavity, suggesting 
residual tumor. Additionally, in the unfiltered Cho/NAA maps, there appears to be residual 
tumor in the anterior tip of the left frontal lobe. However, inspection of the spectra in these 
voxels reveals that the spectra are of insufficient quality to make an accurate assessment of 
pathology. Examples of spectra from eliminated voxels are shown, taken from regions of 
cellular necrosis, low signal-to-noise-ratio, and insufficient lipid suppression. This whole-
brain pipeline is implemented using the Python version of TensorFlow and is portable 
across multiple computer operating systems and hardware, including low and mid-tier 
GPUs. On a system with a low-end GPU (Nvidia GTX 1050 Ti), processing takes less than 
2 minutes. Removing the GPU and running the pipeline only on a multicore CPU (Intel i7-




Figure 0.8: Application of spectral quality CNN to whole-brain metabolite heatmaps. The 
spectral quality CNN can be applied to whole-brain volumes in real-time to assist clinicians 
in making accurate decisions based on sMRI. In a pre-treatment assessment, the CNN 
filters out voxels in the necrotic tumor core, anterior frontal lobe, and multiple voxels in 





The CNN-based spectral quality filter developed in this study was found to perform 
well for detection of inadequate quality spectra, as labeled by a consensus decision of MR 
spectroscopy experts, with an AUC of 0.951, indicating the network has been tuned for 
both high sensitivity and specificity. Furthermore, the network is wrapped into a 
framework that enables rapid deployment of the filter into the clinical research workflow 
and can be applied in under 2 minutes to high resolution EPSI data with whole brain 
coverage. The accuracy achieved is similar to that reported in previous studies using 
machine learning for MR spectral quality analysis, such as those utilizing random forests 
with engineered spectral features (54,55,66). It is difficult to compare results across studies, 
due to variation in study design: how data was collected, the biases of the raters generating 
ground truth, and which parameters were chosen as features. To enable direct comparison 
of performance between the CNN and a machine learning algorithm with engineered 
features, a random forest was built on the same training and testing data collected in 
OSCAR. While the CNN demonstrates slightly better performance, a key advantage of the 
deep learning approach over the random forest is that does not require any engineered 
features generated by spectral fitting. As a result, it is independent of specific features 
derived from fitting algorithms and is compatible with a broader set of pipelines and 
workflows. Of note, the spectra in this work do undergo preliminary linewidth filtering in 
MIDAS prior to being processed by the CNN, which reduced the spectra needed to undergo 
spectral fitting and excluded spectra with broadened metabolite linewidths known to be of 
poor quality. This decision was made to use the status quo of spectral quality filtering as a 
starting point and to develop an algorithm that makes additional improvements to it. In 
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future workflows, applying filtering prior to spectral fitting could reduce the computation 
time for spectral fitting, a time-intensive process, especially since poor quality spectra may 
require considerably more processing during fitting, due to their abnormal shapes.  
While artifacts can occur anywhere in the tissue parenchyma, they are more common 
at air/tissue boundaries due to local magnetic field inhomogeneities and near the periphery 
due to partial volume effects with strong lipid signals in scalp. It is well known that 
magnetic field inhomogeneity occurs in the inferior frontal lobe, anterior temporal lobe, 
and superior to the mastoid air spaces due to magnetic susceptibility differences between 
air and tissue. In patients who have undergone surgery, additional artifacts in EPSI data 
can occur due to magnetic susceptibility from craniotomy staples and possibly from 
hemorrhage. In this first iteration of the spectral quality CNN, this information is not taken 
into account insofar as it is not encoded into the spectrum itself. Future work could include 
the registration of sMRI volumes onto a common anatomical atlas and input the anatomical 
location of each spectrum into the CNN, either in terms of absolute location or relative 
distance from the nearest tissue boundary (i.e. ventricle, dura).  
Additionally, a label collection scheme was implemented to take into account the 
inter-reader variability of spectral evaluation by multiple MR spectroscopy experts. This is 
a key step in improving the generalizability of our algorithm, since each reader is 
independently looking for particular spectral patterns based on his or her own expertise. 
As shown in Table 0.1, there often was disagreement amongst the experts, including 
approximately 5% of data with complete discordance. As such, the performance of 
classifiers reflects subjectivity of the human raters that define the ground truth. Multi-
center and multi-expert analyses have previously been conducted for brain tumor 
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classification, and have shown the necessity of such data in establishing quality control 
norms (83). Inter-rater reliability was assessed by computing the disagreement on spectra 
for every pair of raters, including the seven human spectroscopy experts and the CNN. The 
multidimensional scaling plot in Figure 0.4c shows that the distance between the CNN and 
any of the human raters is not more extreme than the distance between any pair of human 
reviewers, suggesting that the CNN algorithm agrees with humans about as well as humans 
agree with each other. Furthermore, the CNN is close to the geometric center of the human 
raters, which is in accordance with the methodology used to train the CNN; the spatial 
distance can be attributed to consensus scheme used during data labeling, which deviates 
from the mean of the three user labels. The OSCAR platform designed for this work is 
readily available to be used for future sMRI experiments requiring multi-user input. For 
this work, spectroscopy experts were asked to judge the quality of spectra only based on 
the metabolite spectrum and its location in a 2D slice. In reality, experts use additional 
information when assessing spectroscopy data: the strength of the water signal; comparison 
of the fitted and unfitted spectra; and the pathology of the spectrum’s location, e.g. from 
tumor or healthy tissue. These will be added to OSCAR to supplement data collected in 
future studies. 
Another challenge in developing algorithms for spectral quality filtering is the low 
percentage of poor quality voxels present in a whole-brain volume compared to good 
quality voxels, which yields an imbalance in class proportions and consequently can hinder 
algorithm performance (66). In the dataset collected in this work, 72% of spectra were of 
good quality and 28% were of poor quality, which is similar to proportions (65 – 84% 
acceptable spectra) observed in other works (54,55,66). To assess whether balanced class 
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proportions would affect CNN performance, a random minority oversampling scheme was 
implemented, wherein data from the minority class (poor spectra) are randomly sampled 
multiple times to artificially increase the number of samples. A new CNN was trained using 
the same network architecture on this oversampled dataset, with 5991 good quality and 
5991 poor quality, and tuned using Bayesian optimization as described in Methods. The 
resulting AUC was slightly improved compared to the original CNN, at 0.960 (Figure 0.9). 
This suggests that the CNN is robust to the class imbalance of the ground truth dataset, but 
that a more balanced data set could potentially improve outcomes. Of note, the imbalance 
is relatively small, being only a factor of ~2.6, whereas in other domains where deep 
learning has been applied the imbalance can be several orders of magnitude (84).  
Based on the results of GradCAM, the user can glean some insight into how the network 
arrives at a decision. An ideal “good” spectrum is simulated by averaging all spectra 
labeled as “Good”, creating a high signal-to-noise ratio spectrum with all peaks visible 
(Figure 0.7). The GradCAM evaluation of this simulated spectrum suggests that the 
network appears to focus on regions outside of the main metabolite peaks, specifically on 
unsuppressed lipids, unsuppressed water, and the overall baseline waveform. Because all 
spectra evaluated by spectroscopy experts were already passed through a linewidth filter, 
they were known to have metabolite peaks with narrow linewidths and low Cramer-Rao 
bounds. As such, the artifacts are arising from other aspects of the spectrum, and the CNN 
is focusing on these other spectral features. GradCAM visualization also provides a benefit 
over traditional machine learning methods, in that it can localize the band(s) of an 
individual spectrum that explain a CNN classification result. In contrast, interpretation of 
random forests can only be performed on a “population” level, explaining what features 
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are critical in performing classification in the entire dataset, and cannot provide insights 
into the classification of individual spectra. 
In order to incorporate the spectral quality CNN into a clinical research workflow, a 
Python application programming interface to query the CNN from other software was 
developed. The CNN model can perform inference of an entire whole-brain volume on an 
affordable GPU or on a multicore CPU and has been deployed to an in-house sMRI web 
app so that it can be easily applied to clinical studies. While training a CNN is 
computationally intensive and requires powerful GPU hardware, applying the CNN is 
much less intensive and can be done on commodity hardware, either a low-end GPU or a 





Figure 0.9: Effect of class imbalance on CNN performance. To assess the effect of class 
imbalance, a data set was generated via oversampling of the poor quality spectra in the 
original data set, and a CNN was trained on the new data. The oversampled data CNN 





A deep learning algorithm was developed to automatically detect poor quality spectra 
in whole-brain sMRI data that otherwise would lead to incorrect classification of voxel 
pathology. This approach achieved high accuracy when compared to a consensus decision 
from a panel of MR spectroscopy experts, and achieved comparable accuracy to classifiers 
based on engineered features developed in this work and by others. The key advantage of 
the CNN developed here is its ability to operate directly on spectra, enabling quality 
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filtering independent of the fitting algorithm and requiring no engineered features. The 
CNN identifies poor quality spectra and artifacts with a high degree of sensitivity and 
specificity, and has been integrated into a whole-brain spectroscopy processing pipeline. 
Frameworks such as convolutional neural networks are well suited to the high 
dimensionality of sMRI data and can extract information that contributes to spectra quality 
from the spectral waveform beyond what is extracted using engineered features. To provide 
feedback to spectroscopy experts, we also implemented a GradCAM-based visualization 
approach that localizes artifacts in spectra, and that can provide a rationale for classification 
decisions to the user on individual spectra. In this first iteration, the CNN was trained to 
identify spectral quality based only on spectral waveforms with no regard to other factors 
that play a role in experts’ assessments of quality, such as location of the voxel or any 
known pathologies in the brain. Future work will focus on collecting training data and 
developing a CNN that can take these into account, by incorporating an anatomic atlas and 
assessing local pathology. Ultimately, the implementation of an automated spectral quality 
filter will mitigate errors due to incorrect classification of pathology, and assist in pushing 
sMRI into clinical decision-making.   
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Glioblastoma has poor prognosis with inevitable local recurrence despite aggressive 
treatment with surgery and chemoradiation. Radiation therapy (RT) is typically guided by 
contrast-enhanced T1-weighted MRI for defining the high dose target and T2-weighted 
fluid-attenuation inversion recovery (FLAIR) MRI for defining the moderate dose target. 
There is an urgent need for improved imaging methods to better delineate tumors for focal 
RT. Spectroscopic magnetic resonance imaging (sMRI) is a quantitative imaging technique 
that enables whole-brain analysis of endogenous metabolite levels, such as the ratio of 
choline to N-acetylaspartate (Cho/NAA). Previous work has shown that Cho/NAA 
accurately identifies tissue with high tumor burden beyond what is seen on standard 
imaging and can predict regions of metabolic abnormality that are at high risk for 
recurrence.  To facilitate efficient clinical implementation of sMRI for RT planning, we 
developed the Brain Imaging Collaboration Suite (BrICS, https://smri.emory.edu), a 
cloud platform that integrates sMRI with standard imaging and enables team members 
from multiple departments and institutions to work together in delineating RT targets. 
BrICS is being used in a multisite pilot study to assess feasibility and safety of dose-
escalated RT based on metabolic abnormalities in patients with glioblastoma 
(Clinicaltrials.gov NCT03137888). The workflow of analyzing sMRI volumes and 
preparing RT plans is described. The pipeline achieved a rapid turnaround time by enabling 
team members to perform their delegated tasks independently in BrICS when their clinical 
schedules allowed. To date, 18 patients have been treated using targets created in BrICS 




The standard-of-care treatment for glioblastoma, the most common adult primary 
malignant brain tumor, consists of maximal safe surgical resection of tumor followed by 
high dose radiation therapy (RT) with concomitant temozolomide chemotherapy (TMZ) 
(85-88). The standard high dose prescription of 60 Gy is delivered over 30 fractions to 
regions of enhancement on T1-weighted contrast-enhanced (CE-T1w) MRI, in which 
enhancement represents areas of tumor with leaky neovasculature. A lower dose of RT 
(typically 46-54 Gy) is delivered to areas of hyperintensity on T2-weighted fluid-
attenuation inversion recovery (FLAIR) MRI (9). FLAIR hyperintensity corresponds to a 
non-specific combination of tumor and non-tumor pathologies, including inflammation and 
vasogenic edema (89). Despite improvements in maximal resection, concurrent and 
adjuvant chemotherapy, and RT, the median overall survival still remains poor at 15 
months (90,91), with median progression-free survival (PFS) at only 4-6 months (92). 
Recurrent glioblastoma is very difficult to treat, often being resistant to further radiation 
and inaccessible for secondary surgical resection (11). The location of recurrent disease 
can also vary: within the original 60 Gy RT target, within the intermediate dose area, or to 
regions several centimeters away, including crossing the midline (12). Both local and 
distant recurrences need to be addressed to improve progression-free-survival. In a phase 
II study where glioblastomas were treated with high dose proton therapy up to 90 cobalt-
gray equivalent (CGE), it was observed that almost all disease recurred in regions receiving 
less than 70 CGE (93). Thus, it appears that dose escalation may provide sufficient 
tumoricidal doses to achieve local control. However, doses greater than 70 Gy need to be 
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applied selectively to prevent toxicity that could result from excess volumes of normal 
brain being treated to doses of that magnitude. 
Spectroscopic magnetic resonance imaging (sMRI) is an evolution of MR 
spectroscopy (MRS) that enables 3D whole-brain volumes of metabolite levels to be 
obtained in vivo without contrast agents or radioactive tracers (21,94). Two metabolites of 
particular interest in patients with glioblastoma include choline-containing compounds 
(Cho), the building blocks of the cell membrane that increase in proliferating tumor cells, 
and N-acetylaspartate (NAA), a biomarker found in healthy neurons which diminishes due 
to neuronal displacement and death from glial infiltration (21,62). It has been previously 
shown via histological correlation that the ratio of Cho to NAA is significantly elevated in 
glioblastoma due to the opposing changes in these metabolites; in particular, a two-fold 
increase in Cho/NAA compared to healthy tissue in contralateral normal-appearing white 
matter (NAWM) was able to correctly identify tumor in 100% of cases, even when tissue 
samples were biopsied from regions outside of contrast-enhancement per CE-T1w or 
FLAIR hyperintensity (20).  
A combination of dose escalation guided by sMRI, including regions of occult tumor 
normally left untreated by high dose RT, could potentially delay recurrence of disease by 
delivering a cytotoxic dose of radiation to regions of metabolically abnormal tumor even 
if these areas are not detected using standard imaging techniques. However, the use of 
sMRI in clinical practice has been hampered by data processing requirements and limited 
integration into the RT planning workflow. In previous studies, several time-intensive 
manual processing steps were required to import metabolite volumes into clinical imaging 
software so that they could be used in the operating room or for RT planning (19,95). To 
 60
enable integration of sMRI into clinical practice, we have developed a software platform 
designed specifically for the integration of sMRI into the RT planning workflow. In this 
paper, we describe its architecture and demonstrate its features on several sample cases. 
We demonstrate feasibility of this software for collaborative use in a prospective multi-
institutional clinical study to target dose escalated RT based on sMRI. Several challenges 
in integrating this imaging modality into the clinical workflow are addressed, and a sample 
case from the ongoing study is presented to demonstrate that radiation therapy to high risk 
regions can be targeted by quantitative imaging techniques such as sMRI. 
 
1.17 Materials and Methods 
1.17.1 Software Architecture 
To assist with a collaborative clinical study across institutions, we developed the Brain 
Imaging Collaboration Suite (BrICS), a web-based software designed specifically to 
integrate sMRI with clinical 3D MRI volumes, enabling physicians to evaluate relevant 
metabolite levels and the underlying spectra used for this quantitation, and to delineate 
target volumes for RT planning based on this information (96). BrICS consists of two 
components: a centralized server and a lightweight browser client (Figure 0.1a). The server 
performs computations necessary to analyze and display whole-brain spectroscopy; it 
consists of modules written in C++ and the PHP server-side scripting language to take 
advantage of well-established image processing and linear algebra libraries data (97,98). 
The lightweight browser client is written in Javascript and can run on all modern hardware, 
including thin clients such as laptops and tablets. This cloud approach offers several 
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benefits over standalone software clients: 1) improves repeatability and standardization by 
ensuring data are processed on the same hardware; 2) reduces user variability and bias; 3) 
enables real-time deployment of software updates across all clients; 4) prevents the need 
for every end-user to download massive sMRI data sets onto a local computer; 5) runs 
without the need for the user to download any software beyond a web browser, which is of 
key importance since physicians often use restricted hospital workstations; and 6) allows 
information and images to be easily shared with patients who wish to be better informed  
of their clinical management.  
BrICS imports data from spectroscopy processing software, such as the Metabolite 
Imaging and Data Analysis Software (MIDAS), and from other imaging systems/software 
using the Digital Imaging and Communication in Medicine (DICOM) file format. All 
volumes are co-registered using a rigid transformation and resampled using trilinear 
interpolation into a high-resolution T1w image space, enabling overlays of metabolic 
information onto anatomic MRI. Users can then delineate target volumes based on both 
anatomic and spectroscopic information. These targets can be exported as DICOM 
radiation therapy structure sets (DICOM RT) or binary DICOM masks and imported into 




Figure 0.1: Schema of BrICS architecture. a) The Brain Imaging Collaboration Suite 
(BrICS) consists of a centralized server which performs image processing, and a 
lightweight browser client. b) BrICS imports spectroscopy and DICOM-format MRI 
volumes, and can export RT targets to other clinical software.  sMRI volumes are blended 
with clinical MRI, and users can perform tasks such as evaluating underlying spectra and 
contouring based on sMRI abnormalities. 
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1.17.2 Visualization and Contouring 
The main interface of BrICS is shown in Figure 0.2. sMRI volumes – either 
individual metabolites or metabolite ratios – are overlaid on anatomic volumes (e.g. T1w 
MRI), enabling visual assessment of metabolic changes in spatially dependent manner. For 
MR spectroscopists and radiologists familiar with MRS techniques, selection of a voxel 
will bring up the corresponding spectrum. Since sMRI is a quantitative imaging technique, 
voxel intensities can be reliably interpreted across subjects, and decision-making can be 
based on specified thresholds. This ability is built-in to the contouring module; physicians 
can make contours based on the values in sMRI maps (Figure 0.3). For example, the 
Cho/NAA volume abnormality index (20) can be used, as shown, to generate a contour 
around all voxels which have a Cho/NAA abnormality index above a given threshold; users 
can select this threshold and automatically generate contours of increasing or decreasing 
sensitivity of disease detection. Radiologists can then review these contours and make 
changes to them using built-in editing tools (painting, erasing, selection of connected-
components). Once contours are generated, they can be visualized as 3D objects, enabling 
visual quality assessment and correspondence with anatomy. Statistics such as contour 
volume and number of connected components are also reported. 
1.17.3 Normalization of Metabolite Values 
Cerebral concentrations of several macromolecules, including Cho and NAA, are 
known to vary based on a subject’s age, gender, and anatomic location of brain being 
sampled (17). To account for these variations in baseline metabolism, metrics such as the 
Cho/NAA abnormality index (20) and the Cho-NAA-index (42) take into account relative 
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changes in these metabolites compared to normal tissue, typically contralateral normal-
appearing white matter (NAWM) (99). For this trial, we use the Cho/NAA abnormality 
index, defined as the Cho/NAA of a given voxel divided by the mean Cho/NAA value in 
contralateral NAWM. In previous works (19,20,95), NAWM was manually contoured on 
a clinical T1w volume by a neuroradiologist using commercial software, then the mask 




Figure 0.2: The main user interface for BrICS. sMRI metabolite and metabolite ratio maps 





Figure 0.3: The BrICS contouring module. a) The contouring module enables identification 
of target volumes based on either anatomic or metabolite images. For quantitative imaging 
techniques like sMRI, users can automatically delineate contours using threshold values; 
b) A series of targets based on thresholding of the Cho/NAA abnormality index; target 




To expedite this process, remove reliance on commercial software, and mitigate 
user bias, we have implemented an algorithm in BrICS to automatically contour the 
NAWM based on a Gaussian mixture model (100) (Figure 0.4). First, all voxels from the 
cerebrum are masked using an anatomic atlas. Next, all cerebral Cho/NAA voxels are 
modeled as a bimodal Gaussian distribution, with voxels arising from the second, higher-
mean Gaussian population representative of tumor pathology. These voxels are then 
masked, and the side with largest contiguous abnormal segment is selected as the side of 
tumor; voxels in the contralateral hemisphere are segmented into gray and white matter 
based on fractional water content (101) calculated by MIDAS, and then the mean is 
reported as the normalizing factor for the subject’s abnormality index calculations. 
 
1.17.4 Automated Segmentation of Residual Contrast Enhancement 
Additional algorithmic modules can be built into BrICS to assist with other routines 
that are regularly performed by clinicians. One such module automatically contours 
residual contrast enhancing tissue (Figure 0.5), so as to differentiate true unresected tumor 
with leaky neovasculature from blood products due to surgical resection (102). The module 
requires a pre-contrast T1w MRI, a CE-T1w MRI, and a T2w or FLAIR MRI, all of which 
are co-registered into the same imaging space in the axial plane. The pre- and post-contrast 
MR images are histogram normalized and subtracted to generate a difference map; Otsu 
thresholding with four classes is used to identify residual enhancement (103,104). Otsu 
thresholding is applied to the FLAIR map to automatically identify hyperintensity; the 
single largest connected component is used as a bounding mask for the T1w residual 
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volume. Finally, morphological opening and closing filters are applied to the bounded T1w 
residual volume to remove islets and thin anisotropic components, e.g. blood vessels. The 
entire algorithm can be run in < 10 seconds on the BrICS server and yields a final contour 
which can be evaluated and manually edited, if necessary, by a neuroradiologist - saving 





Figure 0.4: Schema of the Gaussian mixture model for NAWM segmentation. NAWM is 
typically contoured manually by radiologists; this algorithm can perform the same 





Figure 0.5: Algorithm for automated residual contrast enhancement segmentation. BrICS 
takes a post-contrast T1w MRI (top), pre-contrast T1w MRI (middle), and a FLAIR MRI 
(bottom) volume, and follows the shown algorithm to rapidly contour residual contrast 
enhancement post-surgical resection. This volume can then be edited manually by the 
neuroradiologist or radiation oncologist as desired to define a dose-escalated volume. 
 
 
1.17.5 Patient Imaging 
To assess the feasibility and safety of sMRI-guided radiation therapy, a multisite 
clinical study funded by NCI was initiated (Clinicaltrials.gov NCT03137888).  Three 
institutions are participating in this pilot study – Emory University, the Johns Hopkins 
University, and the University of Miami – and a total of 30 patients with newly diagnosed 
glioblastoma will be enrolled. Patients enrolled after undergoing maximal safe surgical 
resection or biopsy at the discretion of the neurosurgeon. Enrolled patients were ≥18 years 
of age, had a Karnofsky Performance Score ≥ 60, and were willing to undergo dose-
escalated radiation therapy to 75 Gy.  
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An sMRI scan was obtained up to two weeks prior to starting RT+TMZ. A 15 minute 
echo planar spectroscopic imaging (EPSI) pulse sequence combined with GRAPPA 
(parallel imaging (18)), was performed on a 3T scanner (Siemens Medical Solutions, 
Erlangen, Germany) with a 32-channel or 20-channel head coil array (echo time [TE] = 
50ms, repetition time [TR] = 1551ms, flip angle [FA] = 71 degrees). During the same 
session, a high resolution T1w magnetization prepared rapid acquisition gradient echo 
(MP-RAGE) sequence was obtained at the same orientation and position as the EPSI. Raw 
EPSI data was transformed into spatial-spectral data, co-registered with the MP-RAGE 
volume, and the relative metabolite concentration values were obtained by spectral fitting 
using MIDAS (17,18).  
 
1.17.6 Radiation Therapy Planning 
An outline of the workflow for patients in this study is shown in Figure 0.6. The 
EPSI/GRAPPA and MP-RAGE volumes, in addition to the most recent clinical CE-T1w 
and FLAIR MRI, were imported into BrICS. Automated contours for Cho/NAA 
abnormality index of 2.0 and residual contrast enhancing tissue were generated using the 
algorithms described above. Using BrICS, two MR spectroscopists from different 
institutions collaboratively reviewed the underlying raw and fitted spectra within the 
Cho/NAA abnormal contour and removed voxels with poor spectral quality. Meanwhile, a 
neuroradiologist then reviewed and edited the residual contrast enhancing volume to ensure 
the algorithms accurately captured the target volumes, and validated the residual CE 
volume. The two separate contours were then merged to form a single target volume for 
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high dose RT. Next, an external radiation oncologist (from a non-treating site) edited and 
approved the volume based on anatomy and dose safety concerns. Finally, the treating-site 
radiation oncologist made final edits based on his/her discretion and validated the volume 
for RT treatment. To ensure patient safety and to enable retrospective review of this study, 
all user edits were tracked in BrICS in a digital audit trail. 
The final contour generated in BrICS was defined as gross tumor volume 3 (GTV3). 
The clinical target volume 3 (CTV3) was defined as equal to GTV3 with no margin. In this 
pilot feasibility study, a maximum volume of 65cm3 was allowed for CTV3, approximately 
adhering to the 5 cm diameter boost volume limit used in the NRG Oncology BN001 phase 
II trial on RT dose escalation for glioblastomas (105). The CTV3 contour was exported 
from BrICS as a DICOM RT structure set on the high resolution T1w MP-RAGE volume 
into additional contouring or treatment planning software such as VelocityAI (Varian 
Medical Systems), MIM Maestro (MIM Software Inc), Eclipse (Varian), Pinnacle (Philips 
Healthcare), etc., per the routine of the treating site. Additional standard treatment volumes 
were generated including GTV2, defined as the surgical cavity with residual contrast-
enhancement, and GTV1, defined as hyperintensity on FLAIR MRI.  5mm anatomically-
constrained margins were added to GTV2 and GTV1 to produce CTV2 and CTV1, 
respectively. A 3mm margin was added to all three CTVs to produce the planning target 
volumes (PTV3, PTV2, and PTV1). A simultaneous in-field boost IMRT plan was 
generated to treat PTV3, PTV2, and PTV1 to 75 Gy, 60 Gy, and 51 Gy, respectively, 




Figure 0.6: Radiation therapy planning workflow for sMRI-based dose escalation. After 
patients are enrolled and consented, their imaging data are processed and edited in BrICS. 
The centralized platform enables reliable and repeatable processing, with documented edits 
made by physicians and spectroscopists to prepare the final treatment plan. 
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Table 0.1: Summary of target volume definitions and dose prescriptions. 
Target Name Definition CTV Margin PTV Margin Dose 
GTV3 
Cho/NAA abnormality index ≥ 2 
+ residual contrast enhancement 
0mm 3mm 75 Gy 
GTV2 
(standard of care) 
Contrast enhancing tissue + 
resection cavity 
5mm 3mm 60 Gy 
GTV1 
(standard of care) 





A demo of BrICS is available at https://brainimaging.emory.edu/brics-demo with a 
few curated and de-identified data sets. In addition to the dose-escalated RT study 
described above, BrICS is currently being used for several clinical projects internally at 
Emory University: targeting of biopsies in patients with non-enhancing low-grade gliomas, 
monitoring therapeutic response of patients with glioblastoma receiving a histone-
deacetylase inhibitor in addition to standard chemoradiation, identification of metabolite 
abnormalities associated with melanoma brain metastasis, and a pilot study evaluating the 
benefit of sMRI for patients with mild traumatic brain injury. Additionally, BrICS served 
as the platform for testing new imaging processing algorithms such as a neural network for 
identifying spectral artifacts (106) and autoencoder-based spectral fitting (107). 
RT plans from one patient who underwent dose escalation per this study’s protocol are 
presented in Figure 0.7. The patient is a 21-year-old female diagnosed with a frontal 
glioblastoma and enrolled in the trial one month after undergoing surgical resection of her 
tumor. sMRI volumes were obtained and processed in MIDAS and in BrICS per the 
protocol. The neuroradiologists, spectroscopists, and radiation oncologists accessed BrICS 
remotely for several minutes each, when time was available during their busy schedules. 
Segmentation of residual contrast enhancement by the automated algorithm, followed by 
neuroradiologist review, identified a 1.6 cm3 nodular residual contrast-enhancing lesion 
on the posterior border of the surgical cavity remaining after surgery, typical of patients 
who underwent near total resections (Figure 0.7a). However, the Cho/NAA abnormality 
was much greater with a volume of 50.6 cm3, expanding laterally, anteriorly, and 
posteriorly from the surgical cavity (Figure 0.7b). GTV3 was planned on the union of these 
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two contours and targeted for a 75 Gy boost. The contour for GTV3 was exported as a 
DICOM RT structure and imported into Eclipse for dose planning (Figure 0.7c). Dose 
constraints based on RTOG guidelines to all organs-at-risk (OARs) were met, with greater 




Figure 0.7: Example treatment plan for study patient. a) The patient is a 21-year-old female 
with newly diagnosed glioblastoma with a near-total resection of the tumor. b) However, 
the Cho/NAA map indicates metabolically active tumor expanding outward from the 
resection cavity. c) A boosted dose of 75 Gy (PTV3) was successfully planned and 





Current treatments for glioblastoma are insufficient in achieving local control. This 
is felt to be due in part to limitations of standard imaging methods in identification of 
infiltrating tumor margins, which show no contrast-enhancement, potentially leaving these 
high-risk regions undertreated. Improvements in treatment options, such as with higher 
radiation doses, can only be beneficial if all high-risk tumor regions (both enhancing and 
non-enhancing) are properly targeted. In this work, we develop a software platform that 
successfully enables sMRI integration into the radiation therapy planning workflow. The 
EPSI/GRAPPA sequence can be used on standard 3T instrumentation, and the current 
version of the sequence is available for several different Siemens models (e.g. PRISMA, 
Trio, and Skyra); expansion to other vendors is an ongoing project. The data can then be 
sent to a centralized server for processing, Because it is web-based, BrICS can be used by 
multiple users and institutions without the need for additional software, data, or processing. 
BrICS was successfully used as the infrastructure for an ongoing multi-institutional clinical 
study assessing the feasibility of dose-escalated radiation guided by sMRI in patients with 
glioblastoma; to date, 18 patients have been treated on this protocol, and no toxicities have 
been observed. Thus, there is an urgent need for improved quantitative imaging biomarkers 
that can not only identify these regions, but also be readily incorporated into clinical 
practice.  
sMRI has been shown to delineate infiltrating tumor beyond standard MRI but has 
thus far been only used in retrospective analyses due to the complexity of integrating it 
with clinical volumes, the requirement for an on-site MR spectroscopist to manually review 
spectra in individual voxel, and variability in acquisition and processing across institutions. 
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A web-platform such as BrICS provides solutions for these challenges by enabling 
centralized data storage and analysis, allowing clinicians from multiple institutions to 
utilize sMRI without the need for local experts or software. Users will always have the 
latest version of BrICS without needing to download additional software or data sets and 
can access BrICS from any computer browser. BrICS is currently being used in a multisite 
clinical study assessing the feasibility of sMRI guidance for radiation therapy and will 
continue to be developed as infrastructure for future consortium-level trials. 
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Magnetic resonance spectroscopy imaging (MRSI) has shown great promise in the 
detection and monitoring of neurologic pathologies such as tumor. A necessary component 
of data processing includes the quantitation of each metabolite, typically done through 
fitting a model of the spectrum to the data. For high-resolution volumetric MRSI of the 
brain, which may have ~10,000 spectra, significant processing time is required for spectral 
analysis and generation of metabolite maps. 
1.22.2 Methods 
A novel deep learning architecture that combines a convolutional neural network with 
a priori models of the spectrum is presented. This architecture, a convolutional encoder – 
model decoder (CEMD), combines the strengths of adaptive and unbiased convolutional 
networks with models of magnetic resonance and is readily interpretable. 
1.22.3 Results 
The CEMD architecture performs accurate spectral fitting for volumetric MRSI in 
patients with glioblastoma, provides whole-brain fitting in one minute on a standard 
computer, and handles a variety of spectral artifacts. 
1.22.4 Conclusion 
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A new architecture combining physics domain knowledge with convolutional neural 
networks has been developed and is able to perform rapid spectral fitting of whole-brain 




Proton magnetic resonance spectroscopic imaging (MRSI) is an imaging modality 
capable of generating high-resolution 3D maps of cerebral metabolites concentrations in 
vivo (20,22,62).  Previous studies have shown that altered metabolism identified regions 
of occult tumor that are not visible in contrast-enhanced T1w MRI (20,108,109). Studies 
have assessed the potential of using MRSI to guide radiation therapy (RT) in patients with 
glioblastomas (95,110-112), and an ongoing multisite clinical study is prospectively 
boosting radiation based on this technique (NCT03137888, “Spectroscopic MRI-Guided 
Radiation Therapy Planning in Glioblastoma”) (113). To utilize volumetric MRSI for 
clinical studies, maps of the individual metabolite distributions must be created by 
quantifying the metabolite resonance peaks, a process known as spectral fitting. Several 
spectral fitting algorithms have been established, including ones that operate in both the 
time and frequency domain of the acquired data (114,115). Common amongst these 
techniques is the incorporation of prior knowledge, which includes information on the 
resonance frequencies of metabolites of interest and lineshapes. Several parametric spectral 
analysis methods have developed (26,28-31,116,117), all of which rely on iterative 
optimization procedures to find the model parameters that best match the data. However, 
these methods do not scale well to volumetric spectroscopic imaging, which can contain 
on the order of 10,000 spectra in a whole-brain scan. One method for processing of whole-
brain MRSI is the FITT program of the Metabolite Imaging and Data Analysis System 
(MIDAS) (17,18), which uses iterative time-frequency parametric modelling methods for 
spectral analysis (30). This algorithm is typical of the parametric spectral analysis 
approaches that have been widely applied to MRS. As with other parametric spectral 
 81
analysis methods, spectral fitting with MIDAS is computationally-intensive, requiring 40-
50 minutes on a high-end multicore workstation. However, if MRSI is to be integrated into 
clinical protocols it is critical that all processing be done within a few minutes, ideally on 
board the scanner computer. This would enable rapid quality checks of the final maps to 
see if the scan needs to be repeated before the patient leaves and to be sent for clinical 
review in a timely manner.  
Machine learning has proven to have exceptional utility in medical imaging, 
including MRSI (54,55,58,59,118,119). Hiltunen et. al. described an artificial neural 
network (ANN) architecture that could predict metabolite peak areas from magnitude 
spectra in patients with gliomas (58); Das et. al. presented a multi-layer perceptron (MLP) 
for quantifying metabolite concentrations from synthetically generated spectra and phase-
encoded 2D MRSI using results from LCModel as data for supervised training, achieving 
accurate predictions of metabolite concentrations (61); and Bhat et. al. used an 
unsupervised neural network for analysis of phase-corrected 2D MRSI data (59). While 
these methods provide measures of metabolite concentrations, it is difficult to contextualize 
why the MLP or ANN produced a given output. A concept in machine learning that 
correlates well to curve fitting is the idea of the encoder-decoder, or autoencoder. 
Autoencoders are a type of unsupervised learning neural network that seek to find a 
compressed encoding of input data such that the input data can be accurately reconstructed 
from this parsimonious encoding (120,121). The autoencoder consists of two independent 
neural networks: an encoder, that transforms the input data into a lower dimensional space; 
and a decoder, that reconstructs the original input data from the lower dimensional 
representation (Figure 0.1Error! Reference source not found.). The encoder and decoder 
 82
are concurrently trained to minimize reconstruction error, with the constraint that the 
interim representation has significantly lower dimension than the input, and thus only 
important “features” of the data are maintained. This process is highly analogous to 
parameterized curve fitting, wherein a model (the decoder) uses relatively few parameters 
to reconstruct a denoised version of raw data. With autoencoders, both the encoding and 
decoding models are neural networks (a cascade of convolution, pooling, matrix 
multiplication and summation operations) such that higher-order non-linear features can 
be extracted from the inputs. The model parameters of these neural networks can be 
optimized using gradient descent techniques to minimize reconstruction error. Generally, 
the only constraint on the autoencoder is the size of the lower dimensional representation, 





Figure 0.1: Schema of a general autoencoder. An autoencoder takes an input, s, and seeks 
to encode it into a compressed latent space, z, such that the input can be reconstructed using 




To leverage the feature-learning capabilities of autoencoders while maintaining the 
interpretability of parameters given domain knowledge about MRS, a novel spectral fitting 
algorithm was developed that utilized a convolutional neural network encoder with a 
model-based decoding of the spectrum. We evaluated this method for fitting of singlet 
resonances in MRSI of the brain. We also implemented a software pipeline for rapid 
generation of metabolite maps of interest. Metabolite maps generated using this system 




1.24.1 Image Acquisition and Processing 
Volumetric echo planar spectroscopic imaging (EPSI) scans were performed on 
four healthy subjects and six subjects with newly diagnosed glioblastoma who were 
enrolled in an ongoing clinical trial (NCT03137888). Scans were conducted at 3T (Siemens 
Prisma) with a 32-channel head coil (Siemens Healthineers, Erlangen, Germany). For the 
subjects with glioblastoma, data were obtained following surgical resection but prior to 
radiation therapy and chemotherapy, as previously described (119). Briefly, T1-weighted 
(T1w) magnetization-prepared rapid gradient echo pulse (TR = 1900 ms, TE = 3.52 ms, 
256 x 256 x 160 matrix, flip angle (FA) = 9°) and whole-brain 3D EPSI (TR = 1551 ms, 
TE = 50 ms, 64 x 64 x 32 matrix, FA = 71°) sequences with generalized autocalibrating 
partially parallel acquisitions (GRAPPA) acceleration were obtained during the same 
scanning session, oriented at a +15 degree tilt in the sagittal plane from the anterior 
commissure-posterior commissure line (122). For the EPSI/GRAPPA sequence, an oblique 
saturation band was placed in the sagittal plane from the optic chiasm to the cerebellum. A 
medium TE of 50ms was used to reduce the impact of lipid contamination and emphasize 
the signal of metabolites of interest in subjects with brain tumors: choline (Cho), creatine 
(Cr), and N-acetylasparate (NAA). MIDAS (17,18) was used to perform the following 
preprocessing and volume reconstruction steps: spatial reconstruction, B0 field correction 
using simultaneously-acquired intracellular water signal, co-registration of the T1w and 
metabolite volumes, lipid suppression, and water suppression. The initial processing also 
created a mask covering the brain volume, but excluding voxels for which the water 
linewidth was greater than 18 Hz, as calculated using the T2* map. A total of 102,005 
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spectra were obtained and separated into three data subsets: 85,661 for training; 8,192 for 
validation; and 8,192 for testing. 
For assessing generalizability, additional data from subjects with newly-diagnosed 
glioblastoma that were scanned at Emory University, the University of Miami and the 
Johns Hopkins University, were evaluated. The same sequences and parameters as above 
were used, with the exception that studies at the University of Miami were carried out on 
a 3T Siemens Skyra with a 20-channel head coil. 
 
1.24.2 Convolutional Encoder – Model Decoder 
The goal of spectral fitting for an input spectrum, 𝑠 ∈ ℝ , is to find a parameter set, 
𝜃 ∈ ℝ , 𝑘 ≪ 512, such that when these parameters are used in a spectral model, 𝑔(𝜃), the 
result is a noise-free approximation of the input:  
 𝑔(𝜃): ℝ → ℝ , 𝑔(𝜃) ≈ 𝑠 (1) 
Mathematically, this can be represented as the following optimization task: 
 arg min[𝑔(𝜃) − 𝑠]  (2) 
In this context, the task of finding 𝜃 is the encoding step while the function g(𝜃) is the 
decoding step. In this work, we define the convolutional encoder – model decoder (CEMD) 
architecture. The CEMD architecture is graphically depicted in Figure 0.2.  The encoding 
step in CEMD is a convolutional neural network (CNN) composed of sequential layers of 
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convolution, pooling, and rectification (73,123). Each of these layers is has parameterized 
weights that can collectively be referred to as W; therefore, the CNN with weights W can 
be conceived of as applying a series of transformations that perform the encoding function 
𝑓 ∶  ℝ → ℝ  defined by 𝑓(𝑠, 𝑊) = 𝜃. Training identifies W to minimize the error 
defined in Equation 2.  In the context of spectral fitting, a fixed spectral model is used as 
the decoder (Equation 1) to generate a fitted version of the input spectrum. The overall 
training objective can be stated as: 
 arg min
𝑾
𝑔 𝑓(𝑠, 𝑊) − 𝑠   (3) 
A key point in this optimization is that it requires no “ground truth” or “true” fitted 
spectra for CNN training. It is an unsupervised learning task requiring only a set of spectra, 
𝑆 = {𝑠 , 𝑠 , … , 𝑠 }  ∈  ℝ × , to train the CNN weights with the goal of minimizing the 




Figure 0.2: Schematic of the convolutional encoder – model decoder (CEMD) architecture. 
CEMD uses a convolutional neural network (CNN) to learn a low-rank representation of 
input spectra and uses known models for the baseline and peak components of spectra to 
train the CNN. 
  
 88
The decoder was based on previously described parametric analyses that model a 
spectrum as having two components: i) metabolite resonances that are explicitly defined, 
and ii) a baseline composed of all metabolites and macromolecules not explicitly defined 
(29,30). Metabolite resonances were modeled using the Lorentzian-Gaussian lineshape 
model: 
 
𝑠 =  𝐹𝐹𝑇 𝐴  𝑒 , ∆  𝑒    (4) 
For each metabolite, m, the metabolite model required six parameters: peak amplitude 
𝐴 , resonance frequency 𝜔 , zero and first order phases (𝜙  and 𝜙 ), and Gaussian and 
Lorentzian decay constants (Ta and Tb). The three major singlet resonances at TE = 50 ms 
were modeled: Cho, Cr, and NAA. Note that this formulation returns the relative 
concentrations of each metabolite, not the peak area. A constraint was placed such that all 
three metabolites have the same zero- and first-order phase shifts and linewidths, such that 
only the resonance frequency and amplitude needed to be independently determined. Since 
the expected resonance frequency, defined as 𝜔 , , is known a priori from a library of 
chemical resonances, only a shift in frequency from the expected, ∆𝜔 , needed to be 
calculated. Thus, for these three metabolite singlet resonances, a total of 10 parameters 
were needed: 
 𝜃 = {𝐴 , 𝐴 , 𝐴 , ∆𝜔 , ∆𝜔 , ∆𝜔 , 𝜙 , 𝜙 , 𝑇 , 𝑇 }   (5) 
The baseline component was defined by wavelet reconstruction, using a set of coarse 
(124) third-order Coiflets (125) as the wavelet kernels and four levels of dyadic upsampling 
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to convert 32 coarse coefficients (𝜃 ) into the baseline signal. In order to enable automated 
computation of gradients for training the CNN in TensorFlow (126), wavelet 
reconstruction was implemented as a series of linear matrix operations. At each level, the 
output of the previous iteration, 𝑦 ∈ ℝ , were first dyadically upsampled (127). Dyadic 
upsampling on a vector 𝑦 was implemented as augmentation of its transpose with a vector 
of zeros of the same size, followed by vectorization and transposition: 
 𝑦 = [𝑦 … 𝑦 ]   (6) 
 
 







   (7) 
 𝑦 = 𝑣𝑒𝑐(𝑦 ) = [𝑦 0 𝑦 0 … 𝑦 0]   (8) 
The upsampled vector was then convolved with the Coiflet low-frequency reconstruction 
kernel, 𝐶𝑜𝑖𝑓3  (125): 
 𝑦′ =  𝑦 ∗ 𝐶𝑜𝑖𝑓3     (9) 
The central 2p elements of 𝑦′  were used as the input for the next level of wavelet 
reconstruction. The CEMD encoder therefore needed to calculate 42 coefficients, 10 for 
the metabolite resonances and 32 for the baseline, which are passed to the decoder to create 




Figure 0.3: Detailed schematic of the CEMD architecture. CEMD features two serial 
encoder-decoder steps, the first which computes the baseline, and the second which fits 
resonance peaks on the baseline-subtracted spectrum. FC = fully connected. 
 
 
A more detailed representation of the CEMD architecture is shown in Figure 0.3. Only 
the real component of the complex input spectrum (𝑠 ∈ ℝ ) was passed through a CNN 
during the encoder to produce a low-rank representation that directly corresponded to the 
42 spectral model parameters. The decoder then applied the metabolite resonance and 
baseline models to the low-rank representation and created the fitted spectrum (𝑠′ ∈ ℝ ). 
The training set consisted of N=85,661 frequency domain spectra each consisting of 512. 
The mean and standard deviation of the amplitude, 𝜇  and 𝜎 , were computed across 





    (10) 
While CEMD followed an encode-decode scheme, it consisted of two serial encoder-
decoder stages. First, the normalized spectrum, 𝑠 , was passed through a CNN that 
computed the 32 coarse wavelet coefficients, 𝜃 . This CNN consisted of 13 convolution 
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layers, with max-pooling after the 4th, 8th, and 13th layers, followed by two fully-connected 
(FC) layers (123,128). An estimate of the baseline, 𝑠 , was made from the decoder 
using the wavelet reconstruction technique described in Equations 5-9. Next, the baseline 
was subtracted from the input spectrum: 
 𝑠 = 𝑠 −  𝑠    (11) 
The baseline-subtracted spectrum, 𝑠 , was passed through a second CNN consisting of 
just 6 fully-connected layers that computed the metabolite resonance peak parameters, 𝜃 . 
An estimate of the metabolite resonances, 𝑠 , was made by the decoder using Equation 
4. Next, the baseline and resonance peak estimates were added together to produce an 
estimate of the fitted spectrum, 𝑠 . The root-mean-squared error (RMSE) of the input and 
fitted spectrum was used to update the weights of the encoder CNN, and was calculated as: 
 
𝑠 = 𝑠 , − 𝑠 ,     (12) 
CEMD was developed in the Python programming language using the TensorFlow 1.3 
(Google LLC, Mountain View, CA) library, and trained using TensorFlow’s Adam 
optimizer (78) on a high-end workstation with two Titan X graphical processing units 
(GPUs; Nvidia Corporation, Santa Clara, CA). 
In each epoch of training, spectra in the training data set were run through CEMD to 
produce fitted spectra, RMSE for each spectrum was calculated, and gradient 
backpropagation was performed to update the encoder weights. Then, the spectra in the 
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validation set were run through the CEMD and the validation loss was calculated as the 
sum of RMSEs. Training continued through multiple epochs until the validation loss 
converged. Once the autoencoder was trained and the CNN weights finalized, the testing 
set was used to determine final statistics of CEMD performance. The RMSE was calculated 
for each spectrum in the testing set, and the mean and standard deviation were reported. 
Once training of the CEMD encoder weights was complete, the encoder can be applied to 
spectra to compute the relative concentration of each metabolite resonance based on the 
parameters in the encoder output, 𝜃 .  
 
1.24.3 Whole-brain Mapping 
A software pipeline to perform CEMD fitting on whole-brain MRSI and to generate 
volumetric metabolite and ratios maps was developed. Only voxels within the region 
defined from the brain mask were analyzed, for both the CEMD and MIDAS fitting. While 
training of the CNN required a GPU, the final CEMD was implemented on a central 
processing unit (CPU) architecture consisting of a four-core CPU. To assess the utility of 
generated volumetric for radiation treatment planning, the Cho/NAA ratio map was 
computed for 10 subjects with glioblastoma fitted by CEMD and an existing parametric 
analysis method implemented in MIDAS. Spectral fitting in MIDAS used the METAFIT 
option, which applies three applications of fitting (the FITT program). First, B0 and phase 
corrections are performed, prior to applying a spatial smoothing and fitting of a higher-
SNR copy of the data. Using the initial values from this intermediate result a final spectral 
analysis is performed on the original spectra. After fitting, voxels were excluded from both 
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sets of results based on spectral outlier filters, namely those having values that are more 
than four standard deviations from the mean value within the brain.  
Identification of abnormal Cho/NAA regions was determined from the results of each 
fitting method using the largest single connected component of voxels that had a Cho/NAA 
at least twofold increased compared to the mean value in contralateral normal-appearing 
white matter; this particular threshold was previously determined to be optimal for 
identifying high-risk regions for disease recurrence (20,100,113). The identified regions 
from each result were compared using the Dice similarity coefficient (DSC) (129) and a Z 
test was performed for each subject using the logit transform of the DSC (130). 
 
1.25 Results 
Training time for the CEMD was approximately 4 hours using TensorFlow on a 
workstation with two Nvidia Titan X GPUs. The testing set achieved a mean RMSE of fit 
of 5.0% normalized to the amplitude of the largest peak in each spectrum in the testing set, 
with a standard deviation of 0.6%. Sample spectra from the testing set are shown in Figure 
0.4 with the baseline (red) and peak + baseline (black) fit overlaid on the input spectra 
(gray). CEMD can handle a variety of baseline effects, varying from a relatively flat 
baseline near the peaks of interest (Figure 0.4a) to major shifts that can occur at frequencies 
in the region of lipid or metabolites (Figure 0.4b). Phases can also be determined by the 
model (Figure 0.4c,d). Even if the signal-to-noise ratio is poor, due to partial volume 
effects, magnetic field inhomogeneity, or receiver coil sensitivity, CEMD can identify and 
fit the peak and baseline components.  
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Sample spectra from three subjects with glioblastoma, not included in the training, 
testing, or validation sets, are shown in Figure 0.5. In patients with glioblastoma, voxels 
within the region of active tumor exhibit an increase in Cho and a concomitant decrease in 
NAA (20). The CEMD-fitted spectra (black) are overlaid on the input spectra (gray). 
Subject one (Figure 0.5a,b) was scanned at Emory University; subject two (Figure 0.5c,d) 
was scanned at the University of Miami; and subject three (Figure 0.5e,f) was scanned at 
the Johns Hopkins University. All three subjects were scanned using the protocol defined 
in the Methods section, and data were preprocessed in MIDAS as described. Spectra in the 
left column (Figure 0.5a,c,e) are from voxels in the contralateral normal-appearing 
hemisphere, while spectra in the right column (Figure 0.5b,d,f) are taken from voxels in 




Figure 0.4: Example spectral fittings generated by CEMD. The real components of the 
computed baseline (red) and baseline + peak (black) fits are overlaid on spectra (gray). 
Four different types of baseline and phase shifts are shown to indicate that CEMD is able 




Figure 0.5: Sample spectra (real components) from scans of subjects with glioblastoma. 
Subject 1 (A,B) was scanned at Emory University; subject 2 (C,D) was scanned at the 
University of Miami; and subject 3 (E,F) was scanned at Johns Hopkins University. Spectra 
from regions of healthy tissue (A,C,E) and tumor (B,D,F) are shown. a.u. = arbitrary units. 
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Correlations between the metabolite concentrations and the Cho/NAA ratio, 
calculated by CEMD and MIDAS for the testing set are shown in Figure 0.6. The solid 
blue lines plot the mean value between the two fitting techniques for each bin of values, 
and the shaded blue region indicates +/- 1 standard deviation. Overlaid in light gray are the 
histograms for the distribution of metabolite values computed by MIDAS. The variance of 
CEMD predictions compared to MIDAS is inversely correlated with the number of training 
samples available. While the two algorithms are linear in the regions where most of the 
data are present, CEMD has greater uncertainty at the tail end of the histograms where 
there were fewer training data. 
Figure 0.7 compares the fits by MIDAS (blue) and CEMD (black) for several 
challenging spectra from subjects with glioblastoma. The first (Figure 0.7a) depicts a 
spectrum with a large baseline shift on the right-side of the NAA peak. The second (Figure 
0.7b) shows a spectrum with a large decline of the baseline on the Cho and Cr peaks but a 
flat baseline near the NAA peak. The third (Figure 0.7c) shows a spectrum from a voxel 
near the inferior rim of the surgical cavity, where partial volume effects reduce the apparent 
signal-to-noise ratio and where there is an absence of the NAA peak at 2.0 ppm. The fourth 
(Figure 0.7d) depicts a spectrum from the bone-cortex interface in the temporal; all peaks 
have broadened linewidth and the NAA peak is adjacent to large noise and lipid signal. All 
results show comparable performance for fitting of the metabolite peaks with some 





Figure 0.6: Comparison of metabolite values computed by MIDAS and CEMD.  The gray 
histogram shows the distribution of MIDAS calculations; the dark blue line indicates the 
mean values of CEMD and MIDAS in each histogram bin; the shaded blue region indicates 





Figure 0.7: Comparison of CEMD and MIDAS spectral fittings on challenging spectra. 




Results of the CEMD analysis for studies of a subject with glioblastoma, not 
included in the training set, are shown in Figure 0.8, which shows the individual metabolite 
maps, the Cho/NAA ratio map, and corresponding contrast-enhanced T1-weighted (CE-
T1w) and fluid-attenuated inversion recovery (FLAIR) MRI volumes. Superimposed on 
the CE-T1w image is a contour drawn by a neuroradiologist to indicate contrast enhancing 
tissue and the surgical cavity, regions that would normally be targeted for high dose 




Figure 0.8: Example whole-brain metabolite maps generated by CEMD for a patient with 
glioblastoma. The Cho/NAA volume indicates the presence of metabolically active tumor 
around the resection cavity extending beyond the contrast-enhancing lesion. Color bar 
corresponding to relative Cho/NAA values (compared to contralateral normal-appearing 
white matter) for Cho/NAA image; arbitrary units for metabolite maps. Pink contour 





Cho/NAA abnormality volumes were contoured for CEMD and MIDAS fitting and 
the results are shown in Table 0.1, which includes subject-wise execution time, abnormality 
volumes, and DSC. The mean execution time for whole-brain spectral fitting was 20.6 +/- 
2.8 sec using the CEMD. As a representative example, the execution time for CEMD on 
Subject 6 was broken down as follows: 2.7 seconds to load 11,702 spectra from disk into 
memory; 17.0 seconds to load the CEMD encoder model and to process all spectra; 3.3 
seconds to create volumetric maps for each metabolite and the Cho/NAA ratio and to write 
these maps to disk. On average, CEMD-derived lesion volumes are larger by 1.2 cm3 (P = 
0.83 using a two-tailed paired T test) and in several subjects encapsulated the contours 
produced from the MIDAS analysis. The mean DSC between CEMD and MIDAS was 0.72 
+/- 0.13. In Figure 0.9 and Figure 0.10, Cho/NAA volumes computed by MIDAS and 
CEMD for Subjects 9 and 1, respectively, were qualitatively compared; the contours 
indicate a twofold increase in Cho/NAA compared to contralateral white matter. Isolated 
bright spots are artifacts due to fitting errors and were not contoured. A spectrum from an 
area where the two algorithms had different values of Cho/NAA (white box) is shown for 
each subject, with CEMD fit (black) and MIDAS fit (blue) overlaid on the spectrum (gray). 
Discrepancies occur either due to the calculated ratio being just above or below the 2x 
threshold (Figure 0.10b), or in areas of minimal or poor signal quality and therefore the 









2x Cho/NAA Vol. 





Value CEMD MIDAS 
1 17.8 57.9 56.7 1.2 0.84 0.047 
2 26.3 31.9 35.1 -3.2 0.56 0.410 
3 18.1 72.2 76.0 -3.8 0.87 0.026 
4 21.0 35.9 39.9 -4.1 0.65 0.265 
5 17.4 23.0 39.6 -16.7 0.64 0.277 
6 23.0 5.9 4.0 1.8 0.59 0.366 
7 19.0 105.2 134.1 -28.8 0.86 0.037 
8 20.4 86.9 60.0 26.9 0.75 0.141 
9 20.1 54.9 22.8 32.1 0.57 0.385 
10 23.1 37.7 30.7 7.0 0.81 0.072 
       
Mean 20.6 -- -- 1.2 0.72 -- 
Std. 




Figure 0.9: Comparison of the Cho/NAA volumes generated by MIDAS and CEMD in a 
subject with glioblastoma. Contours indicate Cho/NAA values greater than two-fold the 
value in contralateral normal appearing white matter. The spectrum shown comes from the 




Figure 0.10: A second example of CEMD and MIDAS-generated metabolite maps. A 
comparison of Cho/NAA volumes generated by MIDAS (blue) and CEMD (black) in a 
second subject with glioblastoma, with spectra from the highlighted voxels (white boxes) 
shown. Contours indicate the isoline for Cho/NAA values greater than two-fold the value 




In recent years, machine learning has seen tremendous advances and has shattered 
benchmarks in a variety of fields, including medical imaging applications (128). While 
these deep learning approaches, including CNNs, can outperform less complex models, a 
key issue is that of interpretability. Several techniques, such as gradient-weighted class 
activation mapping (81), seek to elucidate some of the internal workings of CNNs and 
provide insight as to why the CNN predicted a particular output. Even so, this is always 
done in a retrospective fashion after the CNN has already been trained, and thus insights 
cannot be used to modify the algorithm. It is difficult to incorporate a priori domain 
knowledge into deep learning because these techniques are fundamentally data-driven 
rather than model or knowledge driven. However, recent work has suggested that the 
incorporation of domain knowledge may be able to improve the performance of deep 
learning models (131,132). 
In this work, a deep learning approach to spectral fitting that incorporates a priori 
spectral information was developed and evaluated. Spectral fitting is the computational 
bottleneck in processing of volumetric MRSI, largely because the existing methods are 
based on iterative algorithms. The CEMD is an unsupervised deep learning architecture 
that incorporates spectral models to generate an encoding of spectral parameters, which is 
advantageous because it does not require any “ground truth” spectral quantitation for 
training. The predictions of the CEMD have contextual meaning, and the CEMD was 
trained to make these predictions within the constraints of an explicitly defined spectral 
model. Once trained, the CEMD performs spectral fitting on volumetric data in under one 
minute using standard computer hardware. The order of magnitude improvement in fitting 
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time can greatly benefit the clinical adoption of whole-brain MRSI. This architecture could 
be implemented on scanner computers, enabling real-time reconstruction and review of 
data without the need for offloading of data to more specialized computer systems. Fitted 
data and metabolite volumes could then easily be sent to a clinical PACS systems in a 
streamlined fashion. 
Incorporation of knowledge of the spectral model imposes constraints that are 
important for the assessment of spectra. Bhat et. al. previously incorporated spectral models 
in an unsupervised neural network; however, their model was limited in requiring baseline-
corrected spectra as input to their neural network (59). CEMD simultaneously computes 
the baseline and peak components of the spectrum and correctly identifies singlets in 
challenging spectra such as those in Figure 0.4. The spectrum in Figure 0.4c indicates the 
loss of the NAA resonance at 2.0 ppm. It is necessary for a fitting model understand where 
the NAA resonance should be and not attempt to model other peak-like shapes (e.g. at 2.3 
ppm and 1.7 ppm) as NAA. For spectra where asymmetric broadening of peaks occurs, the 
spectral lineshape model dictates that a symmetric peak should be fit (Figure 0.4d). In these 
cases, CEMD performed on par with traditional parametric analysis algorithms such as that 
incorporated in MIDAS.  
For this study only the real part of the complex spectral data was used as input for 
CEMD and in the cost function for updating the CNN weights, though a complex spectral 
model (Equation 4) was used in the decoder. We note that the phase correction terms were 
accurately reported. It is speculated that this occurs through an observation from the 
asymmetry of the lineshape (133). An initial implementation of CEMD using the full 
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complex spectral data found reduced performance (mean fit RMSE of 38%), potentially 
due to the increased number of parameters in the encoder that would need to be trained.  
While the CEMD was trained using data obtained on a single 3T scanner, this study 
has demonstrated generalizability to data acquired on other instruments using the same 
acquisition parameters (Figure 0.5); however, this study has not evaluated the extension to 
other pulse sequence parameters. If studies are to be performed using different acquisition 
schemes, such as with shorter TE, CEMD would have to be retrained. However, training 
does not require many subjects because of the ~10,000 spectra in each study. The CEMD 
could be adapted, e.g. changing the number and type of layers in the encoder and number 
of coefficients in the decoder models, for more resonances, of multiplets of resonances, or 
of metabolites whose resonance peaks are not readily separable (gluatamate and 
glutamine). In general, because the autoencoder scheme does not rely on any external 
“ground truth” data, it can be readily adapted and optimized for different complexities of 
fitting. 
In this work, a comparison between this new fitting paradigm and an existing 
iterative parametric optimization method was performed. The results in Figure 0.6 show 
the correlation between the two algorithms’ estimation of Cho, Cr, and NAA resonances 
and the Cho/NAA ratio on the same set of spectra. In spectroscopy, the acquired spectral 
signal amplitude is uncalibrated, and additional methods are required to apply a signal 
normalization procedure. Ratios, such as Cho/NAA, do not require calibration; however, 
they are more unstable when the denominator is low. As seen in Figure 0.7d, both CEMD 
and MIDAS fitting have high uncertainty for high Cho/NAA values that represent low 
NAA regions.  While individual metabolite resonance maps are shown in Figure 0.8 to 
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assess the ability of CEMD to perform whole-brain fitting, the Cho/NAA maps are used as 
the main comparison between CEMD and an existing parametric analysis (MIDAS) in 
Table 0.1. CEMD achieves a Dice coefficient of 0.72 when compared to MIDAS. A key 
observation is that CEMD can produce similar Cho/NAA volumes to MIDAS while never 
being trained to do so; thus, it independently achieves similar results, which highlights the 
power of unsupervised learning techniques.  
Qualitatively, as seen in Figure 0.9 and Figure 0.10, CEMD produces similar spatial 
distributions of the Cho/NAA ratio as MIDAS in subjects with glioblastoma. Both 
algorithms identify the region of brain with an elevated ratio, though occasionally with 
different contour shape and size when selecting voxels with a Cho/NAA abnormality 
greater than 2x contralateral NAWM (Table 0.1). These differences hold when adjusting 
this threshold on two sample cases, one from a subject with high DSC conformality and 
another with low DSC conformality (Table 0.2).  The study for Subject 9 has poor DSC; 
reviewing spectra in which the two fitting algorithms produced different values of 
Cho/NAA reveals that these discordant fits occur in regions of low spectral SNR 
surrounding the rim of the surgical cavity. Two possible reasons underlying this 
discordance are speculated. The first is highlighted in Figure 0.9, in which CEMD 
estimates a slightly lower value for the NAA resonance peak compared to MIDAS, and 
therefore estimates a Cho/NAA above the 2x threshold. A similar discrepancy in the 
Cho/NAA value can be observed in Subject 1 in the contralateral extension of the CEMD 
contour in Figure 0.10b. While using a threshold of a twofold increase in Cho/NAA 
compared to NAWM has been previously established to identify a high probability of 
tumor, a voxel having a value just below the threshold does not mean the voxel is tumor-
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free. Ultimately, when using MRSI for therapeutic guidance or diagnosis, clinician insight 
is needed.  
 
Table 0.2: Dice coefficients of contours for different Cho/NAA thresholds. 
Subject 3 
Rel. Cho/NAA Threshold 1.75 2.0 2.25 
DSC 0.86 0.87 0.88 
Z test p value 0.04 0.03 0.02 
    
Subject 6 
Rel. Cho/NAA Threshold 1.75 2.0 2.25 
DSC 0.55 0.59 0.51 
Z test p value 0.43 0.37 0.49 
 
 
A second reason for discordance between the two algorithms is apparent in a voxel 
from Subject 1, shown in Figure 0.10a. CEMD has a tendency to overfit spectra with low 
SNR that occur near tissue interfaces, where magnetic field inhomogeneities and partial 
volume effects can cause large distortions. The highlighted voxel is deemed to be 
artifactual and should in fact have been removed. In general, results corresponding to low 
SNR data, as shown in Figures 7 and 8, can be excluded by post-processing that takes into 
account the uncertainty of the fit via metrics such as Cramér-Rao lower bounds (26,45). 
This is especially important when calculating metabolite ratios. One limitation of the 
current implementation of the CEMD fitting is that it does not include an estimate of the 
uncertainties of the fit and this needs to be further investigated, although our previously-
described artifact filter may also be used for this purpose (119). While CEMD was built 
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for spectral fitting for rapid turnaround time, for research purposes in which a more 
thorough analysis of spectral quantitation is desired, existing software such as MIDAS can 
be used.  
 
1.27 Conclusion 
In this work, a machine learning approach to spectral fitting is described that can 
perform sub-minute calculation of relative metabolite concentrations in MRSI of the brain. 
A convolutional encoder-model decoder technique has been implemented that explicitly 
incorporates a standard parametric spectral model with the power of unsupervised feature-
learning to produce fast spectral fittings that are constrained by the standard model. This is 
a powerful paradigm that does not require a priori ground truth and relies upon previously-
used spectral lineshape and baseline models to optimize the underlying convolutional 
neural network parameters. The CEMD architecture is shown to produce accurate fitting 
of a variety of spectra acquired from multiple scanners in patients with glioblastoma, 
including correctly fitting challenging spectra with low SNR, partial volume effects, 
baseline shifts, phase shifts, and dropout of one or more metabolite resonances. The CEMD 
can fit whole-brain data on a standard multicore computer without the need for expensive 
workstations or GPUs, in less than one minute. With this new autoencoder-based neural 
network, the largest computational bottleneck in processing MRSI can be overcome, 
bringing improved performance that will support the implementation of MRS for more 




Proton spectroscopic magnetic resonance imaging (sMRI) is an advanced imaging 
modality that enables the non-invasive detection of in vivo tissue metabolites without the 
need for any exogenous contrast agents. It has been shown to provide diagnostic and 
prognostic value for several neuropathologies, particularly highly proliferative disease 
such as glioblastoma. While it has been a growing area of research, it’s implementation 
clinically has been limited due to several technical challenges. In this dissertation, we 
sought to provide engineering and informatics solutions to four of these challenges. 
In Chapter 2, we present our work on developing a machine learning approach for 
filtering spectral artifacts in whole-brain sMRI. Artifacts are spectra which are of poor 
quality such that accurate quantitation of metabolites cannot be performed. Artifacts are 
due to a variety of causes, including partial volumes, transitions between types at tissue 
boundaries, local magnetic field inhomogeneities, subject motion, low signal-to-noise ratio 
(SNR) causing peaks to be washed out, and improper water or lipid suppression (43). When 
viewing spatial heat maps for sMRI, as shown in Figure 0.2, artifacts can be appear as 
hypo- or hyperintense foci. In order to use sMRI for diagnosis or treatment planning, it is 
important to ensure that erroneous spectra are removed prior to evaluation. The gold 
standard is manual review by an MR spectroscopy expert, and while this is sufficient for 
single and multi-voxel MRS, it does not scale well to whole-brain imaging which contain 
on the order of 10,000 independent spectra. 
Several statistical techniques have been developed to identify artifactual spectra, such 
as measuring linewidths, Cramer-Rao bounds of spectral fitting, SNR analysis, magnitude 
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of peaks, measurement of tissue fraction within a voxel, and detection of insufficient water 
or lipid suppression (18,26,45). A combination of these metrics is, for example, 
implemented in the MIDAS software package, a commonly used application for whole-
brain sMRI processing. However, a percentage of voxels will still make it through these 
filters and will require manual review. 
To address this issue, we developed a convolutional neural network (CNN) architecture 
that sought to mimic the implicit evaluation criteria used by MRS experts. While most 
experts will use some baseline criteria for evaluating spectral quality (e.g. SNR or 
linewidth), there is also some higher-level features they use that cannot be explicitly 
modeled but is rather learned from experience. We designed a data collection program 
(OSCAR) in a manner that enabled a consensus classification of spectra from a panel of 
experts. These data were then used to train a CNN to classify spectra as being of “good” 
or “poor” quality. The CNN showed high sensitivity and specificity (AUC=0.95) and 
showed no preference towards any single expert. We have since implemented the CNN 
into our workflows and can use it when needed to filter out artifactual voxels. 
There are several improvements that can be made to this CNN in future work. When 
tuned to the optimum sensitivity/specificity threshold, the CNN is potentially too 
aggressive in removing voxels near tumor necrotic cavities, as seen in Figure 0.8. During 
data collection with OSCAR, the expert raters were not given any indication of pathology 
beyond the location of the voxel on a T1w slice, and no data regarding pathology was 
explicitly fed to the CNN. An improved architecture may include, for example, a binary 
segmentation of tumor vs non-tumor during data collection and as part of the input to the 
CNN. The spatial distribution of a given metabolite typically does not produce isolated 
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single-voxel differences (it is smooth), whereas an artifact may be limited to a single voxel. 
Taking into account information about neighboring voxels, therefore, could be of use in 
improving detection of artifacts, particularly in and around tumor. Finally, in our work we 
took the approach of using as input non-fitted spectra, such that the algorithm could be 
applied to any pipeline. However, as noted by the success of several other groups 
(54,55,66), features generated by (and dependent on) spectral fitting do contain information 
that is useful for classifying spectral quality. A future model could combine the unbiased 
deep learning approach used in our work with some engineered features from spectral 
fitting. 
In Chapter 3, we develop an algorithm to internally normalize a subject’s sMRI study 
by contralateral normal-appearing white matter. This technique uses the Cho/NAA map, 
which has a two-Gaussian distribution, to separate out healthy vs pathologic voxels, and 
then calculates the mean of the healthy voxels in contralateral white matter. A segmentation 
of the selected voxels can also be applied to other metabolites to generate NAWM-
normalized maps for each of them. This approach has several advantages in that it is 
automated, fast, and not-subjective. However, it does require a high-coverage Cho/NAA 
map, which may not be present in all subjects, and it does not work in cases where there is 
only a single Gaussian source present (e.g. low grade gliomas, healthy controls, other non-
proliferative pathology). To address these, an algorithm that does not depend on any 
particular metabolite would need to be developed. In the time since the work in Chapter 3 
was completed, the developers of the MIDAS software have added such an algorithm, 
which uses tissue fractions of gray matter to detect tumor, since tumor tends to destroy 
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gray matter as visible on T1w MRI, and then select white matter voxels in the opposite 
hemisphere. 
Chapter 3 also introduced BrICS, the Brain Imaging Collaboration Suite. This browser-
based application has enabled clinicians from Emory and other institutions to visualize, 
annotate, and evaluate sMRI for subjects with several pathologies. BrICS is the primary 
software platform being used for NCT03137888, and using it, we have been able to show 
the feasibility of incorporated spectroscopic information when planning radiation therapy 
targets. At the time of writing this Chapter, enrollment is complete for this study, and an 
analysis will be presented after sufficient follow-up data are collected for each subject. 
Since the publication of the work in Chapter 3, we have continued development of 
BrICS to be a platform for more neuropathologies. There are new algorithms for 
segmentation based on T1w, FLAIR, and sMRI information, and the software is able to 
handle any metabolite or combination maps (e.g. ratio or multiplication). We have also 
developed an integration with TensorFlow, such that our existing and future machine 
learning algorithms can be easily called from BrICS. Finally, we have built an integration 
with the REDCap database software package, enabling querying of de-identified data from 
within the HIPAA-compliant database package. BrICS is now deployable as a Docker 
container (source code available upon request at https://github.com/sgurbani/brics), and 
is being developed to be deployable at scale for larger clinical studies. Once the outcomes 
of NCT03137888 have been analyzed, we plan to submit a national consortium trial to 
assess the efficacy of sMRI-guided dose escalation radiation therapy for patients with 
glioblastoma. 
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In Chapter 4, we introduced a novel unsupervised architecture to perform spectral 
quantitation, the convolutional encoder-model decoder (CEMD). In effect, CEMD mimics 
the expectation-maximization task that is performed with iterative algorithms. The 
advantages of this technique over prior work are: 1) it is unsupervised, and so does not 
need to rely on “correct” (e.g. manually reviewed) spectral quantitations; 2) it is 
constrained within known models of magnetic resonance, thereby enabling ready 
interpretability of results; 3) it can correctly model slight frequency shifts from known 
resonances and correctly account for phase shifts; and 4) it can correctly model spectra 
with a variety of baseline signals, including insufficient water and lipid suppression. Once 
CEMD is trained for a particular set of acquisition parameters, it can perform whole-brain 
fitting in less than 30 seconds, a full two orders of magnitude improvement over the current 
state-of-the-art. In the future, CEMD can be expanded to incorporate a broader set of 
metabolites, multiplets of metabolites, and to use different baseline functions if desired. It 
is our goal to one day have CEMD implemented directly on MR instrumentation, such that 
the results of an sMRI scan can be viewed immediately after acquisition, as is the case for 
other MR sequences.   
With these four improvements, we have addressed several of the technical challenges 
that have hindered the clinical implementation of sMRI. We have shown the feasibility of 
using sMRI in the clinical research setting via NCT03137888, and we are preparing for a 
much larger consortium trial to start in the next few years. With continued technical 
development, perhaps sMRI may become a part of the standard-of-care imaging that 
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